drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
listlengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00526 | DB00888 | 1,555 | 1,001 | [
"DDInter1355",
"DDInter1133"
]
| Oxaliplatin | Mechlorethamine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl. | Moderate | 1 | [
[
[
1555,
24,
1001
]
],
[
[
1555,
24,
450
],
[
450,
1,
1001
]
],
[
[
1555,
64,
839
],
[
839,
23,
1001
]
],
[
[
1555,
63,
62
],
[
62,
23,
1001
]
],
[
[
1555,
24,
1539
],
[
1539,
62,
1001
]
],
[
[
1555,
25,
246
],
[
246,
62,
1001
]
],
[
[
1555,
24,
51
],
[
51,
24,
1001
]
],
[
[
1555,
24,
1683
],
[
1683,
63,
1001
]
],
[
[
1555,
63,
1461
],
[
1461,
24,
1001
]
],
[
[
1555,
25,
869
],
[
869,
63,
1001
]
]
]
| [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} (Compound) resembles {v} (Compound)",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
],
[
"Tacrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
]
]
| Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine
Oxaliplatin may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Oxaliplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine |
DB08869 | DB09045 | 162 | 52 | [
"DDInter1773",
"DDInter607"
]
| Tesamorelin | Dulaglutide | Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations. | Moderate | 1 | [
[
[
162,
24,
52
]
],
[
[
162,
63,
170
],
[
170,
23,
52
]
],
[
[
162,
24,
1296
],
[
1296,
63,
52
]
],
[
[
162,
63,
1179
],
[
1179,
24,
52
]
],
[
[
162,
63,
170
],
[
170,
62,
1103
],
[
1103,
23,
52
]
],
[
[
162,
24,
1296
],
[
1296,
62,
1103
],
[
1103,
23,
52
]
],
[
[
162,
63,
1179
],
[
1179,
23,
1103
],
[
1103,
23,
52
]
],
[
[
162,
63,
170
],
[
170,
24,
280
],
[
280,
24,
52
]
],
[
[
162,
24,
1296
],
[
1296,
63,
170
],
[
170,
23,
52
]
],
[
[
162,
63,
1179
],
[
1179,
24,
170
],
[
170,
23,
52
]
]
]
| [
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Tesamorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
]
]
| Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide |
DB00853 | DB09061 | 1,686 | 1,627 | [
"DDInter1762",
"DDInter284"
]
| Temozolomide | Cannabidiol | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy. From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[A32585,A32824]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals . Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors that are found throughout the body. Although THC and CBD have been the most studied cannabinoids, there are many others identified to date including cannabinol (CBN), cannabigerol (CBG), (CBDV), and (THCV) that can be found within the medical cannabis . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms of THC like or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body . Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site which is clinically significant as direct agonists (such as THC) are limited by their psychomimetic effects such as changes to mood, memory, and anxiety. In addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [A31555, A31574]. CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer . In April 2018, a Food and Drug Administration advisory panel unanimously recommended approval of Epidiolex (cannabidiol oral solution) for the treatment of two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome, which are among the two most difficult types of epilepsy to treat [L2721, L2719]. Epidiolex was granted Orphan Drug designation as well as Fast Track Approval from the FDA for further study in these hard to treat conditions. Notably, phase 3 clinical trials of Epidiolex have demonstrated clinically significant improvement in Lennox-Gastaut syndrome and Dravet syndrome . On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. | Moderate | 1 | [
[
[
1686,
24,
1627
]
],
[
[
1686,
24,
384
],
[
384,
23,
1627
]
],
[
[
1686,
63,
597
],
[
597,
23,
1627
]
],
[
[
1686,
24,
1613
],
[
1613,
63,
1627
]
],
[
[
1686,
24,
328
],
[
328,
24,
1627
]
],
[
[
1686,
63,
267
],
[
267,
24,
1627
]
],
[
[
1686,
64,
581
],
[
581,
24,
1627
]
],
[
[
1686,
25,
770
],
[
770,
24,
1627
]
],
[
[
1686,
25,
1510
],
[
1510,
25,
1627
]
],
[
[
1686,
24,
384
],
[
384,
63,
723
],
[
723,
23,
1627
]
]
]
| [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cannabidiol"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
]
]
| Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Temozolomide may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Temozolomide may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Temozolomide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Cannabidiol
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol |
DB00220 | DB06616 | 798 | 594 | [
"DDInter1276",
"DDInter224"
]
| Nelfinavir | Bosutinib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Major | 2 | [
[
[
798,
25,
594
]
],
[
[
798,
24,
883
],
[
883,
1,
594
]
],
[
[
798,
6,
8374
],
[
8374,
45,
594
]
],
[
[
798,
18,
5833
],
[
5833,
46,
594
]
],
[
[
798,
7,
6952
],
[
6952,
46,
594
]
],
[
[
798,
18,
15501
],
[
15501,
57,
594
]
],
[
[
798,
21,
28709
],
[
28709,
60,
594
]
],
[
[
798,
23,
1559
],
[
1559,
24,
594
]
],
[
[
798,
25,
1215
],
[
1215,
24,
594
]
],
[
[
798,
24,
1040
],
[
1040,
63,
594
]
]
]
| [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} (Compound) downregulates {v} (Gene)",
"ACAT2"
],
[
"ACAT2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
]
]
| Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Nelfinavir (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Bosutinib (Compound)
Nelfinavir (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Bosutinib (Compound)
Nelfinavir (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Bosutinib (Compound)
Nelfinavir (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Nelfinavir may lead to a major life threatening interaction when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib |
DB14724 | DB14881 | 48 | 180 | [
"DDInter634",
"DDInter1329"
]
| Emapalumab | Oliceridine | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy. As well, emapalumab was given the status of PRIME by the EMA. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. | Moderate | 1 | [
[
[
48,
24,
180
]
],
[
[
48,
63,
1463
],
[
1463,
24,
129
],
[
129,
25,
180
]
],
[
[
48,
63,
376
],
[
376,
23,
578
],
[
578,
24,
180
]
],
[
[
48,
63,
1463
],
[
1463,
24,
112
],
[
112,
23,
180
]
],
[
[
48,
63,
1197
],
[
1197,
24,
484
],
[
484,
24,
180
]
],
[
[
48,
63,
1463
],
[
1463,
63,
1184
],
[
1184,
24,
180
]
],
[
[
48,
63,
700
],
[
700,
63,
112
],
[
112,
23,
180
]
],
[
[
48,
63,
362
],
[
362,
25,
124
],
[
124,
24,
180
]
],
[
[
48,
63,
1586
],
[
1586,
62,
578
],
[
578,
24,
180
]
],
[
[
48,
63,
1401
],
[
1401,
62,
112
],
[
112,
23,
180
]
]
]
| [
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
],
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
],
[
"Levamlodipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Emapalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oliceridine"
]
]
]
| Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Oliceridine
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Emapalumab may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine |
DB01017 | DB14520 | 1,669 | 1,229 | [
"DDInter1224",
"DDInter1785"
]
| Minocycline | Tetraferric tricitrate decahydrate | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971. | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
1669,
24,
1229
]
],
[
[
1669,
63,
955
],
[
955,
23,
1229
]
],
[
[
1669,
24,
1096
],
[
1096,
23,
1229
]
],
[
[
1669,
63,
954
],
[
954,
24,
1229
]
],
[
[
1669,
1,
1545
],
[
1545,
24,
1229
]
],
[
[
1669,
40,
1572
],
[
1572,
24,
1229
]
],
[
[
1669,
63,
955
],
[
955,
1,
1096
],
[
1096,
23,
1229
]
],
[
[
1669,
24,
1096
],
[
1096,
40,
955
],
[
955,
23,
1229
]
],
[
[
1669,
63,
954
],
[
954,
24,
1096
],
[
1096,
23,
1229
]
],
[
[
1669,
1,
1545
],
[
1545,
24,
955
],
[
955,
23,
1229
]
]
]
| [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} (Compound) resembles {v} (Compound)",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} (Compound) resembles {v} (Compound)",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
]
]
| Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Minocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Minocycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound) and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound) and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Minocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate |
DB12267 | DB14409 | 1,476 | 1,129 | [
"DDInter233",
"DDInter867"
]
| Brigatinib | Human adenovirus e serotype 4 strain cl-68578 antigen | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1476,
24,
1129
]
],
[
[
1476,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1476,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
1476,
62,
168
],
[
168,
24,
1129
]
],
[
[
1476,
25,
676
],
[
676,
63,
1129
]
],
[
[
1476,
24,
1619
],
[
1619,
24,
1129
]
],
[
[
1476,
64,
1057
],
[
1057,
25,
1683
],
[
1683,
24,
1129
]
],
[
[
1476,
63,
1683
],
[
1683,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1476,
62,
168
],
[
168,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1476,
64,
1259
],
[
1259,
64,
1057
],
[
1057,
24,
1129
]
]
]
| [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
]
]
| Brigatinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Brigatinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Brigatinib may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen |
DB11071 | DB14740 | 1,004 | 771 | [
"DDInter1449",
"DDInter881"
]
| Phenyl salicylate | Hyaluronidase | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate may also be found in some antiseptic agents. It is synthesized by heating salicylic acid with phenol, [MSDS]. Phenyl salicylate is used as a food additive in the USA. This compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone). | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. Hyaluronidase was first used in prescription products in the United States on 5 May 2004. | Minor | 0 | [
[
[
1004,
23,
771
]
],
[
[
1004,
63,
167
],
[
167,
23,
771
]
],
[
[
1004,
63,
167
],
[
167,
24,
1438
],
[
1438,
23,
771
]
],
[
[
1004,
63,
617
],
[
617,
63,
1438
],
[
1438,
23,
771
]
],
[
[
1004,
63,
167
],
[
167,
1,
617
],
[
617,
23,
771
]
],
[
[
1004,
63,
617
],
[
617,
40,
167
],
[
167,
23,
771
]
],
[
[
1004,
62,
837
],
[
837,
23,
1479
],
[
1479,
23,
771
]
],
[
[
1004,
62,
101
],
[
101,
62,
1479
],
[
1479,
23,
771
]
],
[
[
1004,
63,
126
],
[
126,
25,
914
],
[
914,
23,
771
]
],
[
[
1004,
63,
500
],
[
500,
64,
914
],
[
914,
23,
771
]
]
]
| [
[
[
"Phenyl salicylate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Phenyl salicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
]
]
| Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyl salicylate may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyl salicylate may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Diflunisal and Diflunisal may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Diflunisal and Diflunisal may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase |
DB09312 | DB10276 | 967 | 1,624 | [
"DDInter103",
"DDInter1623"
]
| Antilymphocyte immunoglobulin (horse) | Rotavirus vaccine | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection. | Major | 2 | [
[
[
967,
25,
1624
]
],
[
[
967,
25,
375
],
[
375,
25,
1624
]
],
[
[
967,
63,
58
],
[
58,
25,
1624
]
],
[
[
967,
64,
908
],
[
908,
25,
1624
]
],
[
[
967,
24,
270
],
[
270,
64,
1624
]
],
[
[
967,
25,
1259
],
[
1259,
64,
1624
]
],
[
[
967,
24,
1531
],
[
1531,
25,
1624
]
],
[
[
967,
25,
375
],
[
375,
64,
617
],
[
617,
24,
1624
]
],
[
[
967,
63,
58
],
[
58,
24,
617
],
[
617,
24,
1624
]
],
[
[
967,
64,
908
],
[
908,
64,
617
],
[
617,
24,
1624
]
]
]
| [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
]
]
| Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Rotavirus vaccine
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may lead to a major life threatening interaction when taken with Rotavirus vaccine
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Rotavirus vaccine
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine |
DB01156 | DB01400 | 593 | 1,372 | [
"DDInter252",
"DDInter1279"
]
| Bupropion | Neostigmine | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MA | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Major | 2 | [
[
[
593,
25,
1372
]
],
[
[
593,
21,
29549
],
[
29549,
60,
1372
]
],
[
[
593,
24,
1383
],
[
1383,
63,
1372
]
],
[
[
593,
25,
1220
],
[
1220,
24,
1372
]
],
[
[
593,
25,
1019
],
[
1019,
63,
1372
]
],
[
[
593,
64,
1573
],
[
1573,
24,
1372
]
],
[
[
593,
25,
497
],
[
497,
25,
1372
]
],
[
[
593,
21,
29549
],
[
29549,
60,
189
],
[
189,
40,
1372
]
],
[
[
593,
21,
29243
],
[
29243,
60,
617
],
[
617,
24,
1372
]
],
[
[
593,
21,
28778
],
[
28778,
60,
1511
],
[
1511,
63,
1372
]
]
]
| [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Osteoarthritis"
],
[
"Osteoarthritis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Osteoarthritis"
],
[
"Osteoarthritis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rivastigmine"
],
[
"Rivastigmine",
"{u} (Compound) resembles {v} (Compound)",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Wheezing"
],
[
"Wheezing",
"{u} (Side Effect) is caused by {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Bupropion",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
]
]
| Bupropion (Compound) causes Osteoarthritis (Side Effect) and Osteoarthritis (Side Effect) is caused by Neostigmine (Compound)
Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Bupropion may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Bupropion may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Bupropion may lead to a major life threatening interaction when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Bupropion may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Neostigmine
Bupropion (Compound) causes Osteoarthritis (Side Effect) and Osteoarthritis (Side Effect) is caused by Rivastigmine (Compound) and Rivastigmine (Compound) resembles Neostigmine (Compound)
Bupropion (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Bupropion (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Mepenzolate (Compound) and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine |
DB00376 | DB00424 | 1,105 | 19 | [
"DDInter1870",
"DDInter896"
]
| Trihexyphenidyl | Hyoscyamine | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as [levodopa]. Trihexyphenidyl was granted FDA approval on 13 May 1949. | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] | Moderate | 1 | [
[
[
1105,
24,
19
]
],
[
[
1105,
24,
85
],
[
85,
63,
19
]
],
[
[
1105,
6,
7420
],
[
7420,
45,
19
]
],
[
[
1105,
10,
11558
],
[
11558,
49,
19
]
],
[
[
1105,
21,
30176
],
[
30176,
60,
19
]
],
[
[
1105,
63,
701
],
[
701,
24,
19
]
],
[
[
1105,
24,
128
],
[
128,
24,
19
]
],
[
[
1105,
1,
1386
],
[
1386,
24,
19
]
],
[
[
1105,
35,
1192
],
[
1192,
63,
19
]
],
[
[
1105,
40,
456
],
[
456,
63,
19
]
]
]
| [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) binds {v} (Gene)",
"CHRM4"
],
[
"CHRM4",
"{u} (Gene) is bound by {v} (Compound)",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) palliates {v} (Disease)",
"Parkinson's disease"
],
[
"Parkinson's disease",
"{u} (Disease) is palliated by {v} (Compound)",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) causes {v} (Side Effect)",
"Angle closure glaucoma"
],
[
"Angle closure glaucoma",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound)",
"Procyclidine"
],
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound)",
"Biperiden"
],
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
]
]
]
| Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Trihexyphenidyl (Compound) binds CHRM4 (Gene) and CHRM4 (Gene) is bound by Hyoscyamine (Compound)
Trihexyphenidyl (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) is palliated by Hyoscyamine (Compound)
Trihexyphenidyl (Compound) causes Angle closure glaucoma (Side Effect) and Angle closure glaucoma (Side Effect) is caused by Hyoscyamine (Compound)
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Trihexyphenidyl (Compound) resembles Procyclidine (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Trihexyphenidyl (Compound) resembles Glycopyrronium (Compound) and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine |
DB08907 | DB09389 | 1,344 | 517 | [
"DDInter280",
"DDInter1315"
]
| Canagliflozin | Norgestrel | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus, [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes. Cardiovascular disease is the most common cause of death in these patients. | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
1344,
24,
517
]
],
[
[
1344,
63,
1254
],
[
1254,
24,
517
]
],
[
[
1344,
24,
1296
],
[
1296,
63,
517
]
],
[
[
1344,
40,
549
],
[
549,
24,
517
]
],
[
[
1344,
24,
1476
],
[
1476,
64,
517
]
],
[
[
1344,
63,
1254
],
[
1254,
63,
1130
],
[
1130,
23,
517
]
],
[
[
1344,
63,
629
],
[
629,
24,
1130
],
[
1130,
23,
517
]
],
[
[
1344,
63,
1411
],
[
1411,
24,
52
],
[
52,
24,
517
]
],
[
[
1344,
24,
1296
],
[
1296,
63,
1130
],
[
1130,
23,
517
]
],
[
[
1344,
40,
549
],
[
549,
63,
1254
],
[
1254,
24,
517
]
]
]
| [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
],
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norgestrel"
]
],
[
[
"Canagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
]
]
| Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Norgestrel
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel |
DB12267 | DB12500 | 1,476 | 283 | [
"DDInter233",
"DDInter714"
]
| Brigatinib | Fedratinib | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1476,
25,
283
]
],
[
[
1476,
24,
907
],
[
907,
23,
283
]
],
[
[
1476,
24,
466
],
[
466,
62,
283
]
],
[
[
1476,
64,
351
],
[
351,
23,
283
]
],
[
[
1476,
63,
479
],
[
479,
23,
283
]
],
[
[
1476,
63,
327
],
[
327,
24,
283
]
],
[
[
1476,
64,
1419
],
[
1419,
24,
283
]
],
[
[
1476,
25,
676
],
[
676,
63,
283
]
],
[
[
1476,
24,
1654
],
[
1654,
63,
283
]
],
[
[
1476,
24,
1619
],
[
1619,
24,
283
]
]
]
| [
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
],
[
"Abametapir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
]
]
| Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Brigatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Brigatinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib |
DB00620 | DB11642 | 175 | 938 | [
"DDInter1855",
"DDInter1480"
]
| Triamcinolone | Pitolisant | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Moderate | 1 | [
[
[
175,
24,
938
]
],
[
[
175,
25,
760
],
[
760,
24,
938
]
],
[
[
175,
24,
28
],
[
28,
24,
938
]
],
[
[
175,
63,
600
],
[
600,
24,
938
]
],
[
[
175,
62,
1018
],
[
1018,
24,
938
]
],
[
[
175,
1,
617
],
[
617,
24,
938
]
],
[
[
175,
23,
1674
],
[
1674,
24,
938
]
],
[
[
175,
40,
870
],
[
870,
24,
938
]
],
[
[
175,
24,
283
],
[
283,
63,
938
]
],
[
[
175,
25,
676
],
[
676,
63,
938
]
]
]
| [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
]
]
| Triamcinolone may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Triamcinolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Triamcinolone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant |
DB05015 | DB11652 | 1,077 | 1,155 | [
"DDInter174",
"DDInter1891"
]
| Belinostat | Tucatinib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Moderate | 1 | [
[
[
1077,
24,
1155
]
],
[
[
1077,
24,
1613
],
[
1613,
24,
1155
]
],
[
[
1077,
63,
267
],
[
267,
24,
1155
]
],
[
[
1077,
24,
214
],
[
214,
63,
1155
]
],
[
[
1077,
24,
1362
],
[
1362,
25,
1155
]
],
[
[
1077,
25,
1510
],
[
1510,
25,
1155
]
],
[
[
1077,
24,
927
],
[
927,
64,
1155
]
],
[
[
1077,
25,
676
],
[
676,
64,
1155
]
],
[
[
1077,
63,
478
],
[
478,
25,
1155
]
],
[
[
1077,
64,
1377
],
[
1377,
25,
1155
]
]
]
| [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
]
]
| Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Tucatinib
Belinostat may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Tucatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Tucatinib
Belinostat may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Tucatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Tucatinib
Belinostat may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tucatinib |
DB00390 | DB01268 | 1,252 | 1,151 | [
"DDInter554",
"DDInter1731"
]
| Digoxin | Sunitinib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
1252,
24,
1151
]
],
[
[
1252,
23,
1311
],
[
1311,
1,
1151
]
],
[
[
1252,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
1252,
7,
3779
],
[
3779,
45,
1151
]
],
[
[
1252,
18,
2035
],
[
2035,
45,
1151
]
],
[
[
1252,
7,
9650
],
[
9650,
46,
1151
]
],
[
[
1252,
18,
5235
],
[
5235,
46,
1151
]
],
[
[
1252,
18,
2415
],
[
2415,
57,
1151
]
],
[
[
1252,
7,
6420
],
[
6420,
57,
1151
]
],
[
[
1252,
21,
29209
],
[
29209,
60,
1151
]
]
]
| [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) resembles {v} (Compound)",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"OXSR1"
],
[
"OXSR1",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"IRAK1"
],
[
"IRAK1",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"HMGCS1"
],
[
"HMGCS1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"AARS"
],
[
"AARS",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} (Compound) downregulates {v} (Gene)",
"INTS3"
],
[
"INTS3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} (Compound) upregulates {v} (Gene)",
"FOSL1"
],
[
"FOSL1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
]
]
| Digoxin may cause a minor interaction that can limit clinical effects when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Digoxin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Digoxin (Compound) upregulates OXSR1 (Gene) and OXSR1 (Gene) is bound by Sunitinib (Compound)
Digoxin (Compound) downregulates IRAK1 (Gene) and IRAK1 (Gene) is bound by Sunitinib (Compound)
Digoxin (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Sunitinib (Compound)
Digoxin (Compound) downregulates AARS (Gene) and AARS (Gene) is upregulated by Sunitinib (Compound)
Digoxin (Compound) downregulates INTS3 (Gene) and INTS3 (Gene) is downregulated by Sunitinib (Compound)
Digoxin (Compound) upregulates FOSL1 (Gene) and FOSL1 (Gene) is downregulated by Sunitinib (Compound)
Digoxin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sunitinib (Compound) |
DB01165 | DB01268 | 1,539 | 1,151 | [
"DDInter1325",
"DDInter1731"
]
| Ofloxacin | Sunitinib | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
1539,
24,
1151
]
],
[
[
1539,
6,
5912
],
[
5912,
45,
1151
]
],
[
[
1539,
21,
29662
],
[
29662,
60,
1151
]
],
[
[
1539,
62,
112
],
[
112,
23,
1151
]
],
[
[
1539,
63,
1148
],
[
1148,
24,
1151
]
],
[
[
1539,
24,
1250
],
[
1250,
63,
1151
]
],
[
[
1539,
25,
1296
],
[
1296,
63,
1151
]
],
[
[
1539,
62,
482
],
[
482,
24,
1151
]
],
[
[
1539,
64,
1179
],
[
1179,
24,
1151
]
],
[
[
1539,
24,
392
],
[
392,
24,
1151
]
]
]
| [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Candida infection"
],
[
"Candida infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
]
]
| Ofloxacin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Sunitinib (Compound)
Ofloxacin (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Sunitinib (Compound)
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Ofloxacin may lead to a major life threatening interaction when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Ofloxacin may lead to a major life threatening interaction when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib |
DB00370 | DB09098 | 1,251 | 98 | [
"DDInter1230",
"DDInter1700"
]
| Mirtazapine | Somatrem | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
1251,
24,
98
]
],
[
[
1251,
24,
159
],
[
159,
63,
98
]
],
[
[
1251,
25,
11
],
[
11,
24,
98
]
],
[
[
1251,
24,
609
],
[
609,
24,
98
]
],
[
[
1251,
25,
985
],
[
985,
63,
98
]
],
[
[
1251,
63,
1010
],
[
1010,
24,
98
]
],
[
[
1251,
63,
1101
],
[
1101,
25,
98
]
],
[
[
1251,
24,
159
],
[
159,
63,
608
],
[
608,
23,
98
]
],
[
[
1251,
25,
11
],
[
11,
25,
1612
],
[
1612,
62,
98
]
],
[
[
1251,
24,
609
],
[
609,
24,
1612
],
[
1612,
62,
98
]
]
]
| [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
]
]
| Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Mirtazapine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Mirtazapine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Mirtazapine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem |
DB01377 | DB08864 | 1,283 | 786 | [
"DDInter1119",
"DDInter1595"
]
| Magnesium oxide | Rilpivirine | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior. | Moderate | 1 | [
[
[
1283,
24,
786
]
],
[
[
1283,
24,
594
],
[
594,
24,
786
]
],
[
[
1283,
63,
1213
],
[
1213,
24,
786
]
],
[
[
1283,
62,
401
],
[
401,
24,
786
]
],
[
[
1283,
24,
286
],
[
286,
63,
786
]
],
[
[
1283,
62,
1194
],
[
1194,
25,
786
]
],
[
[
1283,
24,
1487
],
[
1487,
25,
786
]
],
[
[
1283,
24,
1250
],
[
1250,
35,
786
]
],
[
[
1283,
24,
594
],
[
594,
64,
655
],
[
655,
1,
786
]
],
[
[
1283,
63,
1213
],
[
1213,
24,
655
],
[
655,
1,
786
]
]
]
| [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} (Compound) resembles {v} (Compound)",
"Rilpivirine"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} (Compound) resembles {v} (Compound)",
"Rilpivirine"
]
]
]
| Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may lead to a major life threatening interaction when taken with Rilpivirine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Rilpivirine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) resembles Rilpivirine (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound) |
DB00968 | DB06691 | 1,551 | 849 | [
"DDInter1185",
"DDInter1155"
]
| Methyldopa | Mepyramine | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
1551,
24,
849
]
],
[
[
1551,
24,
272
],
[
272,
24,
849
]
],
[
[
1551,
7,
2216
],
[
2216,
46,
849
]
],
[
[
1551,
63,
1648
],
[
1648,
24,
849
]
],
[
[
1551,
25,
1053
],
[
1053,
24,
849
]
],
[
[
1551,
1,
1266
],
[
1266,
24,
849
]
],
[
[
1551,
23,
1264
],
[
1264,
24,
849
]
],
[
[
1551,
24,
272
],
[
272,
1,
11775
],
[
11775,
40,
849
]
],
[
[
1551,
7,
2216
],
[
2216,
46,
499
],
[
499,
24,
849
]
],
[
[
1551,
63,
1648
],
[
1648,
24,
1594
],
[
1594,
24,
849
]
]
]
| [
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} (Compound) resembles {v} (Compound)",
"Metyrosine"
],
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Phensuximide"
],
[
"Phensuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Methyldopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
]
]
| Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Methyldopa (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Mepyramine (Compound)
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Methyldopa may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Methyldopa (Compound) resembles Metyrosine (Compound) and Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Methyldopa may cause a minor interaction that can limit clinical effects when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Methyldopa (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Phensuximide (Compound) and Phensuximide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB12130 | DB14881 | 1,017 | 180 | [
"DDInter1094",
"DDInter1329"
]
| Lorlatinib | Oliceridine | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. | Major | 2 | [
[
[
1017,
25,
180
]
],
[
[
1017,
64,
124
],
[
124,
24,
180
]
],
[
[
1017,
63,
578
],
[
578,
24,
180
]
],
[
[
1017,
25,
1476
],
[
1476,
24,
180
]
],
[
[
1017,
24,
1619
],
[
1619,
24,
180
]
],
[
[
1017,
62,
1101
],
[
1101,
24,
180
]
],
[
[
1017,
64,
1040
],
[
1040,
25,
180
]
],
[
[
1017,
63,
1154
],
[
1154,
25,
180
]
],
[
[
1017,
24,
877
],
[
877,
25,
180
]
],
[
[
1017,
25,
283
],
[
283,
25,
180
]
]
]
| [
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
]
]
| Lorlatinib may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Lorlatinib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Lorlatinib may lead to a major life threatening interaction when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Oliceridine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Oliceridine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Oliceridine
Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Oliceridine |
DB00041 | DB00819 | 1,648 | 471 | [
"DDInter38",
"DDInter15"
]
| Aldesleukin | Acetazolamide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) | Moderate | 1 | [
[
[
1648,
24,
471
]
],
[
[
1648,
24,
997
],
[
997,
40,
471
]
],
[
[
1648,
24,
1264
],
[
1264,
62,
471
]
],
[
[
1648,
24,
891
],
[
891,
63,
471
]
],
[
[
1648,
24,
251
],
[
251,
24,
471
]
],
[
[
1648,
25,
497
],
[
497,
63,
471
]
],
[
[
1648,
24,
997
],
[
997,
5,
11595
],
[
11595,
44,
471
]
],
[
[
1648,
24,
1264
],
[
1264,
6,
8374
],
[
8374,
45,
471
]
],
[
[
1648,
24,
891
],
[
891,
63,
997
],
[
997,
40,
471
]
],
[
[
1648,
24,
251
],
[
251,
24,
997
],
[
997,
40,
471
]
]
]
| [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
],
[
"Methazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
],
[
"Methazolamide",
"{u} (Compound) treats {v} (Disease)",
"glaucoma"
],
[
"glaucoma",
"{u} (Disease) is treated by {v} (Compound)",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
],
[
"Methazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Acetazolamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
],
[
"Methazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Acetazolamide"
]
]
]
| Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Acetazolamide
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide
Aldesleukin may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) treats glaucoma (Disease) and glaucoma (Disease) is treated by Acetazolamide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Acetazolamide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound) |
DB00400 | DB06655 | 353 | 5 | [
"DDInter843",
"DDInter1077"
]
| Griseofulvin | Liraglutide | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010. | Minor | 0 | [
[
[
353,
23,
5
]
],
[
[
353,
24,
700
],
[
700,
23,
5
]
],
[
[
353,
24,
915
],
[
915,
24,
5
]
],
[
[
353,
24,
192
],
[
192,
63,
5
]
],
[
[
353,
25,
1197
],
[
1197,
24,
5
]
],
[
[
353,
63,
798
],
[
798,
24,
5
]
],
[
[
353,
64,
1336
],
[
1336,
24,
5
]
],
[
[
353,
25,
517
],
[
517,
63,
5
]
],
[
[
353,
62,
168
],
[
168,
24,
5
]
],
[
[
353,
62,
1101
],
[
1101,
25,
5
]
]
]
| [
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
],
[
"Atorvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
],
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
],
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Griseofulvin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Liraglutide"
]
]
]
| Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Griseofulvin may lead to a major life threatening interaction when taken with Norethisterone and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Griseofulvin may lead to a major life threatening interaction when taken with Etonogestrel and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Griseofulvin may lead to a major life threatening interaction when taken with Norgestrel and Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Liraglutide |
DB00015 | DB08875 | 582 | 1,618 | [
"DDInter1585",
"DDInter262"
]
| Reteplase | Cabozantinib | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Major | 2 | [
[
[
582,
25,
1618
]
],
[
[
582,
24,
41
],
[
41,
63,
1618
]
],
[
[
582,
24,
222
],
[
222,
24,
1618
]
],
[
[
582,
24,
885
],
[
885,
25,
1618
]
],
[
[
582,
64,
1578
],
[
1578,
25,
1618
]
],
[
[
582,
25,
273
],
[
273,
25,
1618
]
],
[
[
582,
25,
503
],
[
503,
64,
1618
]
],
[
[
582,
24,
1274
],
[
1274,
37,
1618
]
],
[
[
582,
24,
41
],
[
41,
25,
384
],
[
384,
63,
1618
]
],
[
[
582,
24,
222
],
[
222,
62,
723
],
[
723,
24,
1618
]
]
]
| [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tositumomab"
],
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
]
]
| Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Cabozantinib
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Cabozantinib
Reteplase may lead to a major life threatening interaction when taken with Tositumomab and Tositumomab may lead to a major life threatening interaction when taken with Cabozantinib
Reteplase may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Cabozantinib
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Flurbiprofen may lead to a major life threatening interaction when taken with Cabozantinib
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib |
DB00188 | DB00773 | 168 | 896 | [
"DDInter222",
"DDInter702"
]
| Bortezomib | Etoposide | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | Moderate | 1 | [
[
[
168,
24,
896
]
],
[
[
168,
5,
11555
],
[
11555,
44,
896
]
],
[
[
168,
6,
3486
],
[
3486,
45,
896
]
],
[
[
168,
7,
7972
],
[
7972,
46,
896
]
],
[
[
168,
18,
7335
],
[
7335,
46,
896
]
],
[
[
168,
18,
4112
],
[
4112,
57,
896
]
],
[
[
168,
7,
2186
],
[
2186,
57,
896
]
],
[
[
168,
21,
28681
],
[
28681,
60,
896
]
],
[
[
168,
23,
307
],
[
307,
23,
896
]
],
[
[
168,
24,
441
],
[
441,
23,
896
]
]
]
| [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"COL11A1"
],
[
"COL11A1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} (Compound) downregulates {v} (Gene)",
"LIG1"
],
[
"LIG1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} (Compound) downregulates {v} (Gene)",
"AURKB"
],
[
"AURKB",
"{u} (Gene) is downregulated by {v} (Compound)",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"HSPA1A"
],
[
"HSPA1A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
]
]
| Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Etoposide (Compound)
Bortezomib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Etoposide (Compound)
Bortezomib (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Etoposide (Compound)
Bortezomib (Compound) downregulates LIG1 (Gene) and LIG1 (Gene) is upregulated by Etoposide (Compound)
Bortezomib (Compound) downregulates AURKB (Gene) and AURKB (Gene) is downregulated by Etoposide (Compound)
Bortezomib (Compound) upregulates HSPA1A (Gene) and HSPA1A (Gene) is downregulated by Etoposide (Compound)
Bortezomib (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Etoposide
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a minor interaction that can limit clinical effects when taken with Etoposide |
DB00283 | DB00494 | 701 | 1,533 | [
"DDInter395",
"DDInter646"
]
| Clemastine | Entacapone | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor. | Moderate | 1 | [
[
[
701,
24,
1533
]
],
[
[
701,
24,
1062
],
[
1062,
1,
1533
]
],
[
[
701,
21,
28769
],
[
28769,
60,
1533
]
],
[
[
701,
24,
770
],
[
770,
63,
1533
]
],
[
[
701,
24,
128
],
[
128,
24,
1533
]
],
[
[
701,
35,
1594
],
[
1594,
24,
1533
]
],
[
[
701,
24,
1053
],
[
1053,
64,
1533
]
],
[
[
701,
24,
1062
],
[
1062,
6,
5323
],
[
5323,
45,
1533
]
],
[
[
701,
21,
28769
],
[
28769,
60,
1062
],
[
1062,
1,
1533
]
],
[
[
701,
21,
28698
],
[
28698,
60,
770
],
[
770,
63,
1533
]
]
]
| [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolcapone"
],
[
"Tolcapone",
"{u} (Compound) resembles {v} (Compound)",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolcapone"
],
[
"Tolcapone",
"{u} (Compound) binds {v} (Gene)",
"COMT"
],
[
"COMT",
"{u} (Gene) is bound by {v} (Compound)",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolcapone"
],
[
"Tolcapone",
"{u} (Compound) resembles {v} (Compound)",
"Entacapone"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entacapone"
]
]
]
| Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) resembles Entacapone (Compound)
Clemastine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Entacapone (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Entacapone
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Entacapone
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone (Compound) binds COMT (Gene) and COMT (Gene) is bound by Entacapone (Compound)
Clemastine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Tolcapone (Compound) and Tolcapone (Compound) resembles Entacapone (Compound)
Clemastine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Entacapone |
DB00033 | DB00631 | 342 | 372 | [
"DDInter949",
"DDInter405"
]
| Interferon gamma-1b | Clofarabine | Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Moderate | 1 | [
[
[
342,
24,
372
]
],
[
[
342,
25,
1064
],
[
1064,
25,
372
]
],
[
[
342,
24,
1560
],
[
1560,
24,
372
]
],
[
[
342,
24,
738
],
[
738,
63,
372
]
],
[
[
342,
63,
305
],
[
305,
24,
372
]
],
[
[
342,
25,
1101
],
[
1101,
24,
372
]
],
[
[
342,
25,
593
],
[
593,
63,
372
]
],
[
[
342,
25,
1011
],
[
1011,
64,
372
]
],
[
[
342,
25,
1064
],
[
1064,
40,
11243
],
[
11243,
1,
372
]
],
[
[
342,
24,
1560
],
[
1560,
24,
595
],
[
595,
24,
372
]
]
]
| [
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound)",
"Adenosine monophosphate"
],
[
"Adenosine monophosphate",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
],
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
]
]
| Interferon gamma-1b may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Interferon gamma-1b may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Interferon gamma-1b may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Interferon gamma-1b may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Clofarabine
Interferon gamma-1b may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) resembles Adenosine monophosphate (Compound) and Adenosine monophosphate (Compound) resembles Clofarabine (Compound)
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide and Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine |
DB11978 | DB12364 | 124 | 1,421 | [
"DDInter822",
"DDInter200"
]
| Glasdegib | Betrixaban | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Moderate | 1 | [
[
[
124,
24,
1421
]
],
[
[
124,
63,
1091
],
[
1091,
24,
1421
]
],
[
[
124,
25,
1017
],
[
1017,
24,
1421
]
],
[
[
124,
64,
759
],
[
759,
24,
1421
]
],
[
[
124,
24,
1476
],
[
1476,
24,
1421
]
],
[
[
124,
24,
1339
],
[
1339,
63,
1421
]
],
[
[
124,
64,
1056
],
[
1056,
25,
1421
]
],
[
[
124,
63,
477
],
[
477,
25,
1421
]
],
[
[
124,
24,
1598
],
[
1598,
64,
1421
]
],
[
[
124,
63,
1091
],
[
1091,
24,
1017
],
[
1017,
24,
1421
]
]
]
| [
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telithromycin"
],
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
]
]
| Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Glasdegib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Glasdegib may lead to a major life threatening interaction when taken with Primidone and Primidone may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Glasdegib may lead to a major life threatening interaction when taken with Telithromycin and Telithromycin may lead to a major life threatening interaction when taken with Betrixaban
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Betrixaban
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may lead to a major life threatening interaction when taken with Betrixaban
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban |
DB00030 | DB00624 | 1,685 | 1,561 | [
"DDInter934",
"DDInter1775"
]
| Insulin human | Testosterone | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935. | Moderate | 1 | [
[
[
1685,
24,
1561
]
],
[
[
1685,
24,
155
],
[
155,
1,
1561
]
],
[
[
1685,
24,
870
],
[
870,
63,
1561
]
],
[
[
1685,
24,
1026
],
[
1026,
40,
1561
]
],
[
[
1685,
24,
175
],
[
175,
24,
1561
]
],
[
[
1685,
63,
305
],
[
305,
24,
1561
]
],
[
[
1685,
24,
155
],
[
155,
40,
443
],
[
443,
1,
1561
]
],
[
[
1685,
24,
1438
],
[
1438,
63,
870
],
[
870,
63,
1561
]
],
[
[
1685,
24,
870
],
[
870,
63,
443
],
[
443,
1,
1561
]
],
[
[
1685,
24,
989
],
[
989,
1,
443
],
[
443,
1,
1561
]
]
]
| [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
],
[
"Fluoxymesterone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
],
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
],
[
"Fluoxymesterone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Spironolactone"
],
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
],
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Spironolactone"
],
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
]
]
]
| Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Testosterone (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Testosterone (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Spironolactone (Compound) and Spironolactone (Compound) resembles Testosterone (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone (Compound) resembles Testosterone (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Spironolactone (Compound) and Spironolactone (Compound) resembles Testosterone (Compound) |
DB00703 | DB01169 | 997 | 57 | [
"DDInter1167",
"DDInter120"
]
| Methazolamide | Arsenic trioxide | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Major | 2 | [
[
[
997,
25,
57
]
],
[
[
997,
6,
8374
],
[
8374,
45,
57
]
],
[
[
997,
24,
603
],
[
603,
63,
57
]
],
[
[
997,
24,
480
],
[
480,
24,
57
]
],
[
[
997,
63,
355
],
[
355,
24,
57
]
],
[
[
997,
24,
167
],
[
167,
25,
57
]
],
[
[
997,
64,
1425
],
[
1425,
25,
57
]
],
[
[
997,
63,
870
],
[
870,
25,
57
]
],
[
[
997,
24,
1662
],
[
1662,
64,
57
]
],
[
[
997,
40,
471
],
[
471,
25,
57
]
]
]
| [
[
[
"Methazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Methazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
]
]
| Methazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may lead to a major life threatening interaction when taken with Arsenic trioxide
Methazolamide may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Arsenic trioxide
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may lead to a major life threatening interaction when taken with Arsenic trioxide
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may lead to a major life threatening interaction when taken with Arsenic trioxide
Methazolamide (Compound) resembles Acetazolamide (Compound) and Acetazolamide may lead to a major life threatening interaction when taken with Arsenic trioxide |
DB01320 | DB11569 | 651 | 1,093 | [
"DDInter783",
"DDInter1003"
]
| Fosphenytoin | Ixekizumab | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. | Moderate | 1 | [
[
[
651,
24,
1093
]
],
[
[
651,
62,
608
],
[
608,
24,
1093
]
],
[
[
651,
63,
134
],
[
134,
24,
1093
]
],
[
[
651,
24,
1683
],
[
1683,
24,
1093
]
],
[
[
651,
25,
1409
],
[
1409,
24,
1093
]
],
[
[
651,
64,
629
],
[
629,
24,
1093
]
],
[
[
651,
40,
362
],
[
362,
24,
1093
]
],
[
[
651,
25,
1456
],
[
1456,
63,
1093
]
],
[
[
651,
63,
1057
],
[
1057,
25,
1093
]
],
[
[
651,
25,
676
],
[
676,
64,
1093
]
]
]
| [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
]
]
| Fosphenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Fosphenytoin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Fosphenytoin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Fosphenytoin (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Fosphenytoin may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixekizumab
Fosphenytoin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ixekizumab |
DB00041 | DB00489 | 1,648 | 17 | [
"DDInter38",
"DDInter1704"
]
| Aldesleukin | Sotalol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376] | Moderate | 1 | [
[
[
1648,
24,
17
]
],
[
[
1648,
24,
88
],
[
88,
40,
17
]
],
[
[
1648,
24,
999
],
[
999,
24,
17
]
],
[
[
1648,
24,
1211
],
[
1211,
63,
17
]
],
[
[
1648,
25,
497
],
[
497,
63,
17
]
],
[
[
1648,
24,
1662
],
[
1662,
64,
17
]
],
[
[
1648,
24,
322
],
[
322,
25,
17
]
],
[
[
1648,
25,
1011
],
[
1011,
64,
17
]
],
[
[
1648,
24,
88
],
[
88,
40,
1248
],
[
1248,
40,
17
]
],
[
[
1648,
24,
999
],
[
999,
63,
88
],
[
88,
40,
17
]
]
]
| [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
],
[
"Ioxilan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Atenolol"
],
[
"Atenolol",
"{u} (Compound) resembles {v} (Compound)",
"Sotalol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Sotalol"
]
]
]
| Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan and Ioxilan may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Aldesleukin may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may lead to a major life threatening interaction when taken with Sotalol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Sotalol
Aldesleukin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Sotalol
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Atenolol (Compound) and Atenolol (Compound) resembles Sotalol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound) |
DB00250 | DB01076 | 10 | 700 | [
"DDInter475",
"DDInter133"
]
| Dapsone | Atorvastatin | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal side effects and long term benefits, has resulted in wide use of this medication in North America.[A181087, A181406] Atorvastatin and other statins including [lovastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [simvastatin] are considered first-line treatment options for dyslipidemia.[A181087, A181406] The increasing use of this class of drugs is largely attributed to the rise in cardiovascular diseases (CVD) (such as heart attack, atherosclerosis, angina, peripheral artery disease, and stroke) in many countries. An elevated cholesterol level (elevated low-density lipoprotein (LDL) levels in particular) is a significant risk factor for the development of CVD.[A181087,A181553] Several landmark studies demonstrate that the use of statins is associated with both a reduction in LDL levels and CVD risk.[A181090,A181093,A181096,A181427,A181475,A181538] Statins were shown to reduce the incidences of all-cause mortality, including fatal and non-fatal CVD, as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Some evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within five years) statin use leads to a 20%-22% relative reduction in the number of major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. It is a pentasubstituted pyrrole formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound. Unlike other members of the statin group, atorvastatin is an active compound and therefore does not require activation. | Moderate | 1 | [
[
[
10,
24,
700
]
],
[
[
10,
24,
788
],
[
788,
1,
700
]
],
[
[
10,
6,
10215
],
[
10215,
45,
700
]
],
[
[
10,
24,
896
],
[
896,
24,
700
]
],
[
[
10,
24,
14
],
[
14,
63,
700
]
],
[
[
10,
63,
1324
],
[
1324,
24,
700
]
],
[
[
10,
24,
1377
],
[
1377,
64,
700
]
],
[
[
10,
24,
788
],
[
788,
40,
671
],
[
671,
1,
700
]
],
[
[
10,
24,
671
],
[
671,
1,
788
],
[
788,
1,
700
]
],
[
[
10,
6,
10215
],
[
10215,
45,
671
],
[
671,
1,
700
]
]
]
| [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} (Compound) resembles {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} (Compound) resembles {v} (Compound)",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} (Compound) resembles {v} (Compound)",
"Atorvastatin"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Atorvastatin"
]
]
]
| Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Dapsone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Atorvastatin (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Atorvastatin
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound) and Fluvastatin (Compound) resembles Atorvastatin (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound) and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Dapsone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin (Compound) resembles Atorvastatin (Compound) |
DB00060 | DB08870 | 912 | 850 | [
"DDInter947",
"DDInter228"
]
| Interferon beta-1a | Brentuximab vedotin | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Moderate | 1 | [
[
[
912,
24,
850
]
],
[
[
912,
24,
788
],
[
788,
24,
850
]
],
[
[
912,
24,
1583
],
[
1583,
63,
850
]
],
[
[
912,
63,
305
],
[
305,
24,
850
]
],
[
[
912,
25,
139
],
[
139,
24,
850
]
],
[
[
912,
25,
1510
],
[
1510,
64,
850
]
],
[
[
912,
25,
1377
],
[
1377,
25,
850
]
],
[
[
912,
24,
1011
],
[
1011,
25,
850
]
],
[
[
912,
24,
788
],
[
788,
40,
671
],
[
671,
24,
850
]
],
[
[
912,
24,
1338
],
[
1338,
63,
267
],
[
267,
24,
850
]
]
]
| [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} (Compound) resembles {v} (Compound)",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
],
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
]
]
| Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Interferon beta-1a may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Interferon beta-1a may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Interferon beta-1a may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Brentuximab vedotin
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin |
DB01036 | DB12010 | 211 | 214 | [
"DDInter1832",
"DDInter785"
]
| Tolterodine | Fostamatinib | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
211,
24,
214
]
],
[
[
211,
63,
723
],
[
723,
24,
214
]
],
[
[
211,
24,
1478
],
[
1478,
24,
214
]
],
[
[
211,
23,
741
],
[
741,
24,
214
]
],
[
[
211,
1,
573
],
[
573,
24,
214
]
],
[
[
211,
24,
1017
],
[
1017,
63,
214
]
],
[
[
211,
62,
1424
],
[
1424,
24,
214
]
],
[
[
211,
24,
609
],
[
609,
25,
214
]
],
[
[
211,
63,
723
],
[
723,
24,
976
],
[
976,
24,
214
]
],
[
[
211,
63,
600
],
[
600,
25,
976
],
[
976,
24,
214
]
]
]
| [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
],
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
]
]
| Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tolterodine may cause a minor interaction that can limit clinical effects when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tolterodine (Compound) resembles Fesoterodine (Compound) and Fesoterodine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tolterodine may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib |
DB01126 | DB12010 | 1,260 | 214 | [
"DDInter611",
"DDInter785"
]
| Dutasteride | Fostamatinib | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediator that plays a role in the development and enlargement of the prostate gland. Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to enhance the therapeutic response. Its clinical efficacy against benign prostate hyperplasia in male patients is comparable to that of [finasteride], a specific type II 5α-reductase inhibitor. However, unlike finasteride, dut | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
1260,
24,
214
]
],
[
[
1260,
63,
723
],
[
723,
24,
214
]
],
[
[
1260,
24,
1250
],
[
1250,
24,
214
]
],
[
[
1260,
1,
284
],
[
284,
24,
214
]
],
[
[
1260,
24,
1017
],
[
1017,
63,
214
]
],
[
[
1260,
24,
609
],
[
609,
25,
214
]
],
[
[
1260,
63,
723
],
[
723,
24,
976
],
[
976,
24,
214
]
],
[
[
1260,
24,
1250
],
[
1250,
25,
976
],
[
976,
24,
214
]
],
[
[
1260,
63,
600
],
[
600,
25,
976
],
[
976,
24,
214
]
],
[
[
1260,
24,
1478
],
[
1478,
63,
1428
],
[
1428,
24,
214
]
]
]
| [
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} (Compound) resembles {v} (Compound)",
"Finasteride"
],
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
]
]
| Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dutasteride (Compound) resembles Finasteride (Compound) and Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib |
DB00207 | DB13074 | 1,570 | 877 | [
"DDInter157",
"DDInter1110"
]
| Azithromycin | Macimorelin | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Major | 2 | [
[
[
1570,
25,
877
]
],
[
[
1570,
23,
112
],
[
112,
23,
877
]
],
[
[
1570,
24,
913
],
[
913,
24,
877
]
],
[
[
1570,
24,
485
],
[
485,
25,
877
]
],
[
[
1570,
25,
478
],
[
478,
25,
877
]
],
[
[
1570,
25,
982
],
[
982,
64,
877
]
],
[
[
1570,
63,
521
],
[
521,
25,
877
]
],
[
[
1570,
40,
1056
],
[
1056,
25,
877
]
],
[
[
1570,
23,
112
],
[
112,
23,
1247
],
[
1247,
23,
877
]
],
[
[
1570,
24,
913
],
[
913,
62,
112
],
[
112,
23,
877
]
]
]
| [
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Telithromycin"
],
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
]
]
| Azithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin
Azithromycin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin
Azithromycin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Macimorelin
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Macimorelin
Azithromycin (Compound) resembles Telithromycin (Compound) and Telithromycin may lead to a major life threatening interaction when taken with Macimorelin
Azithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin |
DB00204 | DB01234 | 228 | 1,220 | [
"DDInter580",
"DDInter513"
]
| Dofetilide | Dexamethasone | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Minor | 0 | [
[
[
228,
23,
1220
]
],
[
[
228,
25,
870
],
[
870,
1,
1220
]
],
[
[
228,
23,
891
],
[
891,
40,
1220
]
],
[
[
228,
6,
8374
],
[
8374,
45,
1220
]
],
[
[
228,
18,
6448
],
[
6448,
46,
1220
]
],
[
[
228,
18,
18226
],
[
18226,
57,
1220
]
],
[
[
228,
21,
28890
],
[
28890,
60,
1220
]
],
[
[
228,
24,
688
],
[
688,
23,
1220
]
],
[
[
228,
24,
659
],
[
659,
62,
1220
]
],
[
[
228,
25,
1148
],
[
1148,
23,
1220
]
]
]
| [
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} (Compound) downregulates {v} (Gene)",
"CTSD"
],
[
"CTSD",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} (Compound) downregulates {v} (Gene)",
"GDF15"
],
[
"GDF15",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial infarction"
],
[
"Myocardial infarction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
]
]
| Dofetilide may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone (Compound) resembles Dexamethasone (Compound)
Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dexamethasone (Compound)
Dofetilide (Compound) downregulates CTSD (Gene) and CTSD (Gene) is upregulated by Dexamethasone (Compound)
Dofetilide (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Dexamethasone (Compound)
Dofetilide (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Dexamethasone (Compound)
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Dofetilide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Dexamethasone |
DB06186 | DB15965 | 1,439 | 1,330 | [
"DDInter969",
"DDInter1270"
]
| Ipilimumab | Naxitamab | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors), and is rarely subject to antigen loss. The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of naxitamab therapy markedly simpler than that of its predecessor. | Moderate | 1 | [
[
[
1439,
24,
1330
]
],
[
[
1439,
63,
14
],
[
14,
24,
1330
]
],
[
[
1439,
24,
980
],
[
980,
24,
1330
]
],
[
[
1439,
24,
375
],
[
375,
25,
1330
]
],
[
[
1439,
63,
1057
],
[
1057,
25,
1330
]
],
[
[
1439,
64,
1377
],
[
1377,
25,
1330
]
],
[
[
1439,
25,
1510
],
[
1510,
25,
1330
]
],
[
[
1439,
63,
14
],
[
14,
63,
10
],
[
10,
24,
1330
]
],
[
[
1439,
63,
10
],
[
10,
24,
14
],
[
14,
24,
1330
]
],
[
[
1439,
24,
980
],
[
980,
23,
1193
],
[
1193,
23,
1330
]
]
]
| [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naxitamab"
]
]
]
| Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Naxitamab
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Naxitamab
Ipilimumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Naxitamab
Ipilimumab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Naxitamab
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab |
DB00047 | DB00852 | 176 | 1,445 | [
"DDInter932",
"DDInter1545"
]
| Insulin glargine | Pseudoephedrine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis. Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927. | Moderate | 1 | [
[
[
176,
24,
1445
]
],
[
[
176,
24,
73
],
[
73,
24,
1445
]
],
[
[
176,
24,
280
],
[
280,
40,
1445
]
],
[
[
176,
23,
1203
],
[
1203,
62,
1445
]
],
[
[
176,
24,
1340
],
[
1340,
63,
1445
]
],
[
[
176,
24,
551
],
[
551,
25,
1445
]
],
[
[
176,
24,
1529
],
[
1529,
74,
1445
]
],
[
[
176,
24,
1466
],
[
1466,
35,
1445
]
],
[
[
176,
24,
1161
],
[
1161,
75,
1445
]
],
[
[
176,
24,
73
],
[
73,
35,
280
],
[
280,
40,
1445
]
]
]
| [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Monopotassium phosphate"
],
[
"Monopotassium phosphate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deserpidine"
],
[
"Deserpidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
]
]
]
| Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine (Compound) resembles Pseudoephedrine (Compound)
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Monopotassium phosphate and Monopotassium phosphate may cause a minor interaction that can limit clinical effects when taken with Pseudoephedrine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Deserpidine and Deserpidine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may lead to a major life threatening interaction when taken with Pseudoephedrine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine (Compound) resembles Pseudoephedrine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine (Compound) resembles Pseudoephedrine (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline (Compound) resembles Pseudoephedrine (Compound) and Selegiline may lead to a major life threatening interaction when taken with Pseudoephedrine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Mephentermine (Compound) and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine (Compound) resembles Pseudoephedrine (Compound) |
DB00023 | DB01124 | 305 | 1,411 | [
"DDInter127",
"DDInter1828"
]
| Asparaginase Escherichia coli | Tolbutamide | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
305,
24,
1411
]
],
[
[
305,
24,
959
],
[
959,
40,
1411
]
],
[
[
305,
24,
1347
],
[
1347,
23,
1411
]
],
[
[
305,
24,
1478
],
[
1478,
63,
1411
]
],
[
[
305,
24,
831
],
[
831,
24,
1411
]
],
[
[
305,
25,
1377
],
[
1377,
24,
1411
]
],
[
[
305,
24,
1299
],
[
1299,
25,
1411
]
],
[
[
305,
24,
959
],
[
959,
40,
694
],
[
694,
1,
1411
]
],
[
[
305,
24,
245
],
[
245,
1,
11499
],
[
11499,
40,
1411
]
],
[
[
305,
24,
1347
],
[
1347,
62,
245
],
[
245,
40,
1411
]
]
]
| [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolazamide"
],
[
"Tolazamide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glisoxepide"
],
[
"Glisoxepide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
]
]
| Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may lead to a major life threatening interaction when taken with Tolbutamide
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glisoxepide (Compound) and Glisoxepide (Compound) resembles Tolbutamide (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound) |
DB00685 | DB09122 | 1,299 | 1,613 | [
"DDInter1887",
"DDInter1409"
]
| Trovafloxacin | Peginterferon beta-1a | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
1299,
24,
1613
]
],
[
[
1299,
24,
1274
],
[
1274,
24,
1613
]
],
[
[
1299,
63,
1503
],
[
1503,
24,
1613
]
],
[
[
1299,
23,
1224
],
[
1224,
24,
1613
]
],
[
[
1299,
62,
816
],
[
816,
24,
1613
]
],
[
[
1299,
64,
1101
],
[
1101,
24,
1613
]
],
[
[
1299,
25,
1377
],
[
1377,
25,
1613
]
],
[
[
1299,
24,
1274
],
[
1274,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1299,
63,
1503
],
[
1503,
24,
795
],
[
795,
24,
1613
]
],
[
[
1299,
23,
1224
],
[
1224,
24,
1627
],
[
1627,
24,
1613
]
]
]
| [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemtuzumab ozogamicin"
],
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pemoline"
],
[
"Pemoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
]
]
| Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Gemtuzumab ozogamicin and Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Trovafloxacin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Trovafloxacin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Pemoline and Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a |
DB00673 | DB01263 | 723 | 859 | [
"DDInter112",
"DDInter1494"
]
| Aprepitant | Posaconazole | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
723,
24,
859
]
],
[
[
723,
6,
8374
],
[
8374,
45,
859
]
],
[
[
723,
21,
28762
],
[
28762,
60,
859
]
],
[
[
723,
62,
1101
],
[
1101,
23,
859
]
],
[
[
723,
24,
384
],
[
384,
63,
859
]
],
[
[
723,
63,
254
],
[
254,
24,
859
]
],
[
[
723,
24,
959
],
[
959,
24,
859
]
],
[
[
723,
23,
466
],
[
466,
63,
859
]
],
[
[
723,
24,
39
],
[
39,
64,
859
]
],
[
[
723,
25,
1670
],
[
1670,
64,
859
]
]
]
| [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
]
]
| Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Aprepitant (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Posaconazole
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Posaconazole
Aprepitant may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Posaconazole |
DB08895 | DB14783 | 976 | 287 | [
"DDInter1825",
"DDInter574"
]
| Tofacitinib | Diroximel fumarate | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Major | 2 | [
[
[
976,
25,
287
]
],
[
[
976,
64,
1101
],
[
1101,
24,
287
]
],
[
[
976,
25,
812
],
[
812,
24,
287
]
],
[
[
976,
63,
1430
],
[
1430,
24,
287
]
],
[
[
976,
64,
1510
],
[
1510,
25,
287
]
],
[
[
976,
25,
676
],
[
676,
64,
287
]
],
[
[
976,
25,
375
],
[
375,
25,
287
]
],
[
[
976,
64,
1101
],
[
1101,
64,
1560
],
[
1560,
24,
287
]
],
[
[
976,
25,
812
],
[
812,
63,
599
],
[
599,
24,
287
]
],
[
[
976,
64,
1083
],
[
1083,
24,
384
],
[
384,
24,
287
]
]
]
| [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
],
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
],
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
]
]
| Tofacitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tofacitinib may lead to a major life threatening interaction when taken with Siltuximab and Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tofacitinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Tofacitinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Tofacitinib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Diroximel fumarate
Tofacitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tofacitinib may lead to a major life threatening interaction when taken with Siltuximab and Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Tofacitinib may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB00581 | DB09078 | 355 | 1,228 | [
"DDInter1018",
"DDInter1036"
]
| Lactulose | Lenvatinib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Moderate | 1 | [
[
[
355,
24,
1228
]
],
[
[
355,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
355,
24,
938
],
[
938,
63,
1228
]
],
[
[
355,
24,
609
],
[
609,
24,
1228
]
],
[
[
355,
23,
286
],
[
286,
63,
1228
]
],
[
[
355,
24,
1069
],
[
1069,
25,
1228
]
],
[
[
355,
63,
1176
],
[
1176,
25,
1228
]
],
[
[
355,
24,
982
],
[
982,
64,
1228
]
],
[
[
355,
63,
1100
],
[
1100,
23,
112
],
[
112,
23,
1228
]
],
[
[
355,
24,
938
],
[
938,
62,
112
],
[
112,
23,
1228
]
]
]
| [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
]
]
| Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Lenvatinib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lenvatinib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib |
DB00748 | DB00980 | 662 | 969 | [
"DDInter297",
"DDInter1564"
]
| Carbinoxamine | Ramelteon | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks. | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
662,
24,
969
]
],
[
[
662,
6,
8374
],
[
8374,
45,
969
]
],
[
[
662,
21,
28714
],
[
28714,
60,
969
]
],
[
[
662,
35,
100
],
[
100,
24,
969
]
],
[
[
662,
63,
1242
],
[
1242,
24,
969
]
],
[
[
662,
35,
649
],
[
649,
63,
969
]
],
[
[
662,
24,
407
],
[
407,
63,
969
]
],
[
[
662,
24,
104
],
[
104,
24,
969
]
],
[
[
662,
63,
475
],
[
475,
25,
969
]
],
[
[
662,
6,
8374
],
[
8374,
45,
100
],
[
100,
24,
969
]
]
]
| [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramelteon"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
]
]
| Carbinoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound)
Carbinoxamine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Carbinoxamine (Compound) resembles Brompheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Carbinoxamine (Compound) resembles Clofedanol (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Ramelteon
Carbinoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Brompheniramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon |
DB00927 | DB01390 | 1,559 | 1,117 | [
"DDInter712",
"DDInter1683"
]
| Famotidine | Sodium bicarbonate | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
1559,
23,
1117
]
],
[
[
1559,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
1559,
62,
109
],
[
109,
23,
1117
]
],
[
[
1559,
23,
263
],
[
263,
62,
1117
]
],
[
[
1559,
25,
1213
],
[
1213,
24,
1117
]
],
[
[
1559,
24,
594
],
[
594,
63,
1117
]
],
[
[
1559,
25,
1406
],
[
1406,
63,
1117
]
],
[
[
1559,
63,
362
],
[
362,
24,
1117
]
],
[
[
1559,
24,
665
],
[
665,
24,
1117
]
],
[
[
1559,
21,
29093
],
[
29093,
60,
1220
],
[
1220,
23,
1117
]
]
]
| [
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Famotidine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
]
]
| Famotidine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Duloxetine and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Famotidine may cause a minor interaction that can limit clinical effects when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Famotidine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Famotidine may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Famotidine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate |
DB00976 | DB11113 | 1,056 | 657 | [
"DDInter1758",
"DDInter307"
]
| Telithromycin | Castor oil | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. | Moderate | 1 | [
[
[
1056,
24,
657
]
],
[
[
1056,
25,
927
],
[
927,
63,
657
]
],
[
[
1056,
25,
1491
],
[
1491,
24,
657
]
],
[
[
1056,
63,
891
],
[
891,
24,
657
]
],
[
[
1056,
64,
1181
],
[
1181,
24,
657
]
],
[
[
1056,
24,
1342
],
[
1342,
24,
657
]
],
[
[
1056,
1,
1570
],
[
1570,
24,
657
]
],
[
[
1056,
24,
823
],
[
823,
63,
657
]
],
[
[
1056,
35,
609
],
[
609,
24,
657
]
],
[
[
1056,
25,
927
],
[
927,
63,
1079
],
[
1079,
24,
657
]
]
]
| [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
]
]
| Telithromycin may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telithromycin may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telithromycin may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telithromycin (Compound) resembles Azithromycin (Compound) and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Telithromycin may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil |
DB01081 | DB06282 | 1,688 | 516 | [
"DDInter571",
"DDInter1053"
]
| Diphenoxylate | Levocetirizine | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1688,
24,
516
]
],
[
[
1688,
63,
614
],
[
614,
24,
516
]
],
[
[
1688,
24,
697
],
[
697,
24,
516
]
],
[
[
1688,
24,
1293
],
[
1293,
63,
516
]
],
[
[
1688,
35,
1301
],
[
1301,
24,
516
]
],
[
[
1688,
40,
576
],
[
576,
24,
516
]
],
[
[
1688,
1,
1349
],
[
1349,
24,
516
]
],
[
[
1688,
63,
614
],
[
614,
63,
701
],
[
701,
24,
516
]
],
[
[
1688,
24,
697
],
[
697,
63,
1031
],
[
1031,
23,
516
]
],
[
[
1688,
24,
1293
],
[
1293,
63,
701
],
[
701,
24,
516
]
]
]
| [
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
],
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
],
[
"Valbenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
],
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
],
[
"Dexmedetomidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
],
[
"Valbenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
]
]
| Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine and Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine and Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Diphenoxylate (Compound) resembles Levacetylmethadol (Compound) and Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Diphenoxylate (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Diphenoxylate (Compound) resembles Meperidine (Compound) and Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine and Dexmedetomidine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine and Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine |
DB00584 | DB01390 | 610 | 1,117 | [
"DDInter638",
"DDInter1683"
]
| Enalapril | Sodium bicarbonate | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
610,
23,
1117
]
],
[
[
610,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
610,
24,
1220
],
[
1220,
23,
1117
]
],
[
[
610,
40,
1638
],
[
1638,
23,
1117
]
],
[
[
610,
63,
663
],
[
663,
23,
1117
]
],
[
[
610,
1,
954
],
[
954,
23,
1117
]
],
[
[
610,
24,
1479
],
[
1479,
24,
1117
]
],
[
[
610,
63,
590
],
[
590,
24,
1117
]
],
[
[
610,
21,
29093
],
[
29093,
60,
1220
],
[
1220,
23,
1117
]
],
[
[
610,
24,
1220
],
[
1220,
21,
29093
],
[
29093,
60,
1117
]
]
]
| [
[
[
"Enalapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sodium bicarbonate"
]
]
]
| Enalapril (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Enalapril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Enalapril (Compound) resembles Quinapril (Compound) and Quinapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Enalapril (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound) |
DB00976 | DB08901 | 1,056 | 1,468 | [
"DDInter1758",
"DDInter1492"
]
| Telithromycin | Ponatinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1056,
25,
1468
]
],
[
[
1056,
25,
478
],
[
478,
24,
1468
]
],
[
[
1056,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
1056,
21,
29351
],
[
29351,
60,
1468
]
],
[
[
1056,
24,
379
],
[
379,
23,
1468
]
],
[
[
1056,
63,
1559
],
[
1559,
23,
1468
]
],
[
[
1056,
24,
286
],
[
286,
62,
1468
]
],
[
[
1056,
25,
1135
],
[
1135,
62,
1468
]
],
[
[
1056,
63,
353
],
[
353,
24,
1468
]
],
[
[
1056,
64,
147
],
[
147,
24,
1468
]
]
]
| [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Phosphatase alkaline increased"
],
[
"Phosphatase alkaline increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
]
]
| Telithromycin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Telithromycin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Telithromycin (Compound) causes Phosphatase alkaline increased (Side Effect) and Phosphatase alkaline increased (Side Effect) is caused by Ponatinib (Compound)
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Telithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Telithromycin may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib |
DB08815 | DB09073 | 154 | 951 | [
"DDInter1104",
"DDInter1379"
]
| Lurasidone | Palbociclib | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy. | Moderate | 1 | [
[
[
154,
24,
951
]
],
[
[
154,
24,
1033
],
[
1033,
63,
951
]
],
[
[
154,
25,
283
],
[
283,
63,
951
]
],
[
[
154,
64,
600
],
[
600,
24,
951
]
],
[
[
154,
24,
578
],
[
578,
24,
951
]
],
[
[
154,
63,
761
],
[
761,
24,
951
]
],
[
[
154,
25,
1593
],
[
1593,
24,
951
]
],
[
[
154,
25,
129
],
[
129,
25,
951
]
],
[
[
154,
64,
609
],
[
609,
25,
951
]
],
[
[
154,
25,
1604
],
[
1604,
64,
951
]
]
]
| [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Lurasidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
]
]
| Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lurasidone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lurasidone may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lurasidone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Lurasidone may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Palbociclib
Lurasidone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Palbociclib
Lurasidone may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Palbociclib |
DB00531 | DB12825 | 450 | 1,375 | [
"DDInter456",
"DDInter1032"
]
| Cyclophosphamide | Lefamulin | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity. | Moderate | 1 | [
[
[
450,
24,
1375
]
],
[
[
450,
24,
112
],
[
112,
23,
1375
]
],
[
[
450,
35,
1532
],
[
1532,
24,
1375
]
],
[
[
450,
25,
976
],
[
976,
24,
1375
]
],
[
[
450,
24,
1419
],
[
1419,
24,
1375
]
],
[
[
450,
63,
1324
],
[
1324,
24,
1375
]
],
[
[
450,
25,
676
],
[
676,
63,
1375
]
],
[
[
450,
62,
597
],
[
597,
24,
1375
]
],
[
[
450,
24,
913
],
[
913,
25,
1375
]
],
[
[
450,
25,
1011
],
[
1011,
25,
1375
]
]
]
| [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
]
]
| Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Cyclophosphamide (Compound) resembles Ifosfamide (Compound) and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Cyclophosphamide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Cyclophosphamide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Lefamulin
Cyclophosphamide may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Lefamulin |
DB06176 | DB09020 | 1,342 | 28 | [
"DDInter1616",
"DDInter212"
]
| Romidepsin | Bisacodyl | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956 but has been used as a laxative since 1952. | Moderate | 1 | [
[
[
1342,
24,
28
]
],
[
[
1342,
63,
739
],
[
739,
24,
28
]
],
[
[
1342,
64,
540
],
[
540,
24,
28
]
],
[
[
1342,
24,
938
],
[
938,
63,
28
]
],
[
[
1342,
25,
982
],
[
982,
63,
28
]
],
[
[
1342,
24,
1250
],
[
1250,
24,
28
]
],
[
[
1342,
25,
1593
],
[
1593,
24,
28
]
],
[
[
1342,
63,
739
],
[
739,
21,
28809
],
[
28809,
60,
28
]
],
[
[
1342,
64,
540
],
[
540,
63,
272
],
[
272,
40,
28
]
],
[
[
1342,
24,
938
],
[
938,
63,
662
],
[
662,
1,
28
]
]
]
| [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound)",
"Bisacodyl"
]
]
]
| Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Romidepsin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Romidepsin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Romidepsin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Romidepsin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Bisacodyl (Compound)
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Bisacodyl (Compound) |
DB00757 | DB01203 | 1,166 | 699 | [
"DDInter581",
"DDInter1255"
]
| Dolasetron | Nadolol | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979. | Major | 2 | [
[
[
1166,
25,
699
]
],
[
[
1166,
25,
729
],
[
729,
1,
699
]
],
[
[
1166,
21,
28882
],
[
28882,
60,
699
]
],
[
[
1166,
25,
609
],
[
609,
62,
699
]
],
[
[
1166,
24,
286
],
[
286,
62,
699
]
],
[
[
1166,
25,
1154
],
[
1154,
63,
699
]
],
[
[
1166,
40,
85
],
[
85,
24,
699
]
],
[
[
1166,
25,
1264
],
[
1264,
24,
699
]
],
[
[
1166,
24,
770
],
[
770,
24,
699
]
],
[
[
1166,
24,
1276
],
[
1276,
63,
699
]
]
]
| [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Penbutolol"
],
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} (Compound) resembles {v} (Compound)",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
[
"Alectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
]
]
| Dolasetron may lead to a major life threatening interaction when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Dolasetron (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Nadolol (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Nadolol
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Nadolol
Dolasetron may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Dolasetron (Compound) resembles Atropine (Compound) and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Dolasetron may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Nadolol |
DB00477 | DB08899 | 216 | 129 | [
"DDInter363",
"DDInter649"
]
| Chlorpromazine | Enzalutamide | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
216,
24,
129
]
],
[
[
216,
24,
918
],
[
918,
1,
129
]
],
[
[
216,
6,
8374
],
[
8374,
45,
129
]
],
[
[
216,
21,
28921
],
[
28921,
60,
129
]
],
[
[
216,
23,
112
],
[
112,
23,
129
]
],
[
[
216,
63,
79
],
[
79,
24,
129
]
],
[
[
216,
24,
1148
],
[
1148,
24,
129
]
],
[
[
216,
24,
659
],
[
659,
63,
129
]
],
[
[
216,
1,
1237
],
[
1237,
24,
129
]
],
[
[
216,
25,
1487
],
[
1487,
24,
129
]
]
]
| [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} (Compound) resembles {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
]
| Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Chlorpromazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Chlorpromazine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Chlorpromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Chlorpromazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB01172 | DB09268 | 416 | 1,662 | [
"DDInter1004",
"DDInter1464"
]
| Kanamycin | Picosulfuric acid | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
416,
24,
1662
]
],
[
[
416,
62,
1252
],
[
1252,
23,
1662
]
],
[
[
416,
63,
1027
],
[
1027,
24,
1662
]
],
[
[
416,
24,
1558
],
[
1558,
24,
1662
]
],
[
[
416,
64,
1441
],
[
1441,
24,
1662
]
],
[
[
416,
74,
361
],
[
361,
24,
1662
]
],
[
[
416,
24,
1381
],
[
1381,
63,
1662
]
],
[
[
416,
62,
608
],
[
608,
24,
1662
]
],
[
[
416,
40,
355
],
[
355,
24,
1662
]
],
[
[
416,
62,
1252
],
[
1252,
1,
1482
],
[
1482,
23,
1662
]
]
]
| [
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoxitin"
],
[
"Cefoxitin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacitracin"
],
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
],
[
"Neomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
],
[
"Plazomicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} (Compound) resembles {v} (Compound)",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Kanamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Picosulfuric acid"
]
]
]
| Kanamycin may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin and Cefoxitin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Kanamycin may lead to a major life threatening interaction when taken with Bacitracin and Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Kanamycin (Compound) resembles Neomycin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Kanamycin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Kanamycin (Compound) resembles Lactulose (Compound) and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Kanamycin may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid |
DB08870 | DB09052 | 850 | 250 | [
"DDInter228",
"DDInter220"
]
| Brentuximab vedotin | Blinatumomab | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.[A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients. In March 2018, it was approved under the FDA’s accelerated approval program for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. Full approval for this indication was granted in June 2023.[L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery. | Moderate | 1 | [
[
[
850,
24,
250
]
],
[
[
850,
24,
949
],
[
949,
63,
250
]
],
[
[
850,
24,
637
],
[
637,
24,
250
]
],
[
[
850,
63,
305
],
[
305,
24,
250
]
],
[
[
850,
64,
581
],
[
581,
25,
250
]
],
[
[
850,
25,
1510
],
[
1510,
25,
250
]
],
[
[
850,
63,
593
],
[
593,
25,
250
]
],
[
[
850,
25,
1137
],
[
1137,
64,
250
]
],
[
[
850,
24,
949
],
[
949,
63,
1362
],
[
1362,
63,
250
]
],
[
[
850,
24,
1412
],
[
1412,
63,
267
],
[
267,
24,
250
]
]
]
| [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
],
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
]
]
| Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Brentuximab vedotin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Blinatumomab
Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Blinatumomab
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Blinatumomab
Brentuximab vedotin may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Blinatumomab
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab |
DB00980 | DB14568 | 969 | 982 | [
"DDInter1564",
"DDInter1000"
]
| Ramelteon | Ivosidenib | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Moderate | 1 | [
[
[
969,
24,
982
]
],
[
[
969,
63,
1101
],
[
1101,
23,
982
]
],
[
[
969,
24,
770
],
[
770,
24,
982
]
],
[
[
969,
63,
1559
],
[
1559,
24,
982
]
],
[
[
969,
24,
159
],
[
159,
63,
982
]
],
[
[
969,
24,
1297
],
[
1297,
25,
982
]
],
[
[
969,
63,
600
],
[
600,
25,
982
]
],
[
[
969,
63,
1101
],
[
1101,
23,
271
],
[
271,
23,
982
]
],
[
[
969,
24,
770
],
[
770,
63,
112
],
[
112,
23,
982
]
],
[
[
969,
63,
1559
],
[
1559,
62,
112
],
[
112,
23,
982
]
]
]
| [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
]
]
| Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ivosidenib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib |
DB11967 | DB15035 | 710 | 503 | [
"DDInter210",
"DDInter1959"
]
| Binimetinib | Zanubrutinib | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia. | Major | 2 | [
[
[
710,
25,
503
]
],
[
[
710,
63,
868
],
[
868,
24,
503
]
],
[
[
710,
24,
1320
],
[
1320,
24,
503
]
],
[
[
710,
64,
39
],
[
39,
25,
503
]
],
[
[
710,
63,
1593
],
[
1593,
25,
503
]
],
[
[
710,
63,
868
],
[
868,
24,
1094
],
[
1094,
24,
503
]
],
[
[
710,
24,
1320
],
[
1320,
63,
1094
],
[
1094,
24,
503
]
],
[
[
710,
63,
951
],
[
951,
63,
1094
],
[
1094,
24,
503
]
],
[
[
710,
63,
1250
],
[
1250,
25,
982
],
[
982,
24,
503
]
],
[
[
710,
24,
1619
],
[
1619,
25,
982
],
[
982,
24,
503
]
]
]
| [
[
[
"Binimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
]
]
| Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Binimetinib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib |
DB01101 | DB10795 | 60 | 221 | [
"DDInter285",
"DDInter1486"
]
| Capecitabine | Poliovirus type 1 antigen (formaldehyde inactivated) | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. | Moderate | 1 | [
[
[
60,
24,
221
]
],
[
[
60,
64,
581
],
[
581,
24,
221
]
],
[
[
60,
63,
599
],
[
599,
24,
221
]
],
[
[
60,
24,
384
],
[
384,
24,
221
]
],
[
[
60,
25,
1510
],
[
1510,
24,
221
]
],
[
[
60,
23,
309
],
[
309,
24,
221
]
],
[
[
60,
62,
147
],
[
147,
24,
221
]
],
[
[
60,
25,
676
],
[
676,
63,
221
]
],
[
[
60,
24,
738
],
[
738,
63,
221
]
],
[
[
60,
64,
581
],
[
581,
25,
36
],
[
36,
24,
221
]
]
]
| [
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
]
]
| Capecitabine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Capecitabine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Capecitabine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Capecitabine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) |
DB06663 | DB08827 | 1,154 | 990 | [
"DDInter1398",
"DDInter1085"
]
| Pasireotide | Lomitapide | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1154,
25,
990
]
],
[
[
1154,
21,
28903
],
[
28903,
60,
990
]
],
[
[
1154,
64,
77
],
[
77,
24,
990
]
],
[
[
1154,
63,
761
],
[
761,
24,
990
]
],
[
[
1154,
25,
1297
],
[
1297,
63,
990
]
],
[
[
1154,
24,
951
],
[
951,
63,
990
]
],
[
[
1154,
64,
79
],
[
79,
25,
990
]
],
[
[
1154,
63,
305
],
[
305,
25,
990
]
],
[
[
1154,
25,
1510
],
[
1510,
64,
990
]
],
[
[
1154,
24,
384
],
[
384,
64,
990
]
]
]
| [
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} (Compound) causes {v} (Side Effect)",
"Dry skin"
],
[
"Dry skin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
]
]
| Pasireotide (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Lomitapide (Compound)
Pasireotide may lead to a major life threatening interaction when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pasireotide may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pasireotide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may lead to a major life threatening interaction when taken with Lomitapide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Lomitapide
Pasireotide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Lomitapide
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Lomitapide |
DB00384 | DB00470 | 1,275 | 530 | [
"DDInter1859",
"DDInter601"
]
| Triamterene | Dronabinol | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function . | Moderate | 1 | [
[
[
1275,
24,
530
]
],
[
[
1275,
24,
1614
],
[
1614,
40,
530
]
],
[
[
1275,
21,
28921
],
[
28921,
60,
530
]
],
[
[
1275,
24,
1376
],
[
1376,
63,
530
]
],
[
[
1275,
1,
706
],
[
706,
63,
530
]
],
[
[
1275,
63,
1648
],
[
1648,
24,
530
]
],
[
[
1275,
24,
497
],
[
497,
64,
530
]
],
[
[
1275,
24,
1614
],
[
1614,
6,
3800
],
[
3800,
45,
530
]
],
[
[
1275,
21,
28921
],
[
28921,
60,
1614
],
[
1614,
40,
530
]
],
[
[
1275,
24,
1376
],
[
1376,
63,
1614
],
[
1614,
40,
530
]
]
]
| [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} (Compound) resembles {v} (Compound)",
"Lamotrigine"
],
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} (Compound) binds {v} (Gene)",
"CNR1"
],
[
"CNR1",
"{u} (Gene) is bound by {v} (Compound)",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
]
]
]
| Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Triamterene (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Dronabinol (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Triamterene (Compound) resembles Lamotrigine (Compound) and Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Dronabinol
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) binds CNR1 (Gene) and CNR1 (Gene) is bound by Dronabinol (Compound)
Triamterene (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Nabilone (Compound) and Nabilone (Compound) resembles Dronabinol (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound) |
DB01155 | DB11730 | 872 | 351 | [
"DDInter813",
"DDInter1588"
]
| Gemifloxacin | Ribociclib | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Moderate | 1 | [
[
[
872,
24,
351
]
],
[
[
872,
62,
112
],
[
112,
23,
351
]
],
[
[
872,
63,
355
],
[
355,
24,
351
]
],
[
[
872,
23,
1532
],
[
1532,
24,
351
]
],
[
[
872,
62,
372
],
[
372,
24,
351
]
],
[
[
872,
64,
1486
],
[
1486,
24,
351
]
],
[
[
872,
24,
1491
],
[
1491,
24,
351
]
],
[
[
872,
25,
1220
],
[
1220,
24,
351
]
],
[
[
872,
24,
129
],
[
129,
25,
351
]
],
[
[
872,
24,
1297
],
[
1297,
64,
351
]
]
]
| [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
]
]
| Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gemifloxacin may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gemifloxacin may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib |
DB08904 | DB11601 | 375 | 1,270 | [
"DDInter342",
"DDInter1889"
]
| Certolizumab pegol | Tuberculin purified protein derivative | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
375,
24,
1270
]
],
[
[
375,
64,
350
],
[
350,
24,
1270
]
],
[
[
375,
25,
119
],
[
119,
63,
1270
]
],
[
[
375,
25,
1456
],
[
1456,
24,
1270
]
],
[
[
375,
63,
599
],
[
599,
24,
1270
]
],
[
[
375,
64,
350
],
[
350,
63,
1531
],
[
1531,
24,
1270
]
],
[
[
375,
64,
550
],
[
550,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
375,
64,
1064
],
[
1064,
25,
350
],
[
350,
24,
1270
]
],
[
[
375,
25,
119
],
[
119,
63,
1531
],
[
1531,
24,
1270
]
],
[
[
375,
64,
322
],
[
322,
64,
550
],
[
550,
24,
1270
]
]
]
| [
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab"
],
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
]
| Certolizumab pegol may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Certolizumab pegol may lead to a major life threatening interaction when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Certolizumab pegol may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Certolizumab pegol may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Certolizumab pegol may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Certolizumab pegol may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Certolizumab pegol may lead to a major life threatening interaction when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Certolizumab pegol may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB01114 | DB01202 | 272 | 1,435 | [
"DDInter362",
"DDInter1046"
]
| Chlorpheniramine | Levetiracetam | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions. | Moderate | 1 | [
[
[
272,
24,
1435
]
],
[
[
272,
21,
28769
],
[
28769,
60,
1435
]
],
[
[
272,
63,
701
],
[
701,
24,
1435
]
],
[
[
272,
74,
1376
],
[
1376,
24,
1435
]
],
[
[
272,
24,
820
],
[
820,
63,
1435
]
],
[
[
272,
24,
1264
],
[
1264,
24,
1435
]
],
[
[
272,
21,
28769
],
[
28769,
60,
663
],
[
663,
23,
1435
]
],
[
[
272,
21,
28860
],
[
28860,
60,
475
],
[
475,
24,
1435
]
],
[
[
272,
63,
701
],
[
701,
18,
4930
],
[
4930,
57,
1435
]
],
[
[
272,
63,
475
],
[
475,
6,
4973
],
[
4973,
45,
1435
]
]
]
| [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) causes {v} (Side Effect)",
"Mental disability"
],
[
"Mental disability",
"{u} (Side Effect) is caused by {v} (Compound)",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
"Levetiracetam"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Levetiracetam"
]
]
]
| Chlorpheniramine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Levetiracetam (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Chlorpheniramine (Compound) resembles Diphenhydramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Chlorpheniramine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Methotrexate (Compound) and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Levetiracetam
Chlorpheniramine (Compound) causes Mental disability (Side Effect) and Mental disability (Side Effect) is caused by Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Levetiracetam
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Levetiracetam (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levetiracetam (Compound) |
DB00207 | DB00261 | 1,570 | 702 | [
"DDInter157",
"DDInter93"
]
| Azithromycin | Anagrelide | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated. | Major | 2 | [
[
[
1570,
25,
702
]
],
[
[
1570,
6,
7950
],
[
7950,
45,
702
]
],
[
[
1570,
18,
4884
],
[
4884,
57,
702
]
],
[
[
1570,
21,
28769
],
[
28769,
60,
702
]
],
[
[
1570,
23,
112
],
[
112,
62,
702
]
],
[
[
1570,
24,
1031
],
[
1031,
63,
702
]
],
[
[
1570,
25,
1154
],
[
1154,
64,
702
]
],
[
[
1570,
24,
1674
],
[
1674,
64,
702
]
],
[
[
1570,
40,
1056
],
[
1056,
64,
702
]
],
[
[
1570,
63,
600
],
[
600,
25,
702
]
]
]
| [
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} (Compound) downregulates {v} (Gene)",
"POLR2I"
],
[
"POLR2I",
"{u} (Gene) is downregulated by {v} (Compound)",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Telithromycin"
],
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
],
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
]
]
]
| Azithromycin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Anagrelide (Compound)
Azithromycin (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Anagrelide (Compound)
Azithromycin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Anagrelide (Compound)
Azithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Anagrelide
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide
Azithromycin may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Anagrelide
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may lead to a major life threatening interaction when taken with Anagrelide
Azithromycin (Compound) resembles Telithromycin (Compound) and Telithromycin may lead to a major life threatening interaction when taken with Anagrelide
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Anagrelide |
DB01618 | DB09272 | 776 | 412 | [
"DDInter1239",
"DDInter632"
]
| Molindone | Eluxadoline | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283) | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. | Moderate | 1 | [
[
[
776,
24,
412
]
],
[
[
776,
63,
1594
],
[
1594,
24,
412
]
],
[
[
776,
24,
830
],
[
830,
24,
412
]
],
[
[
776,
64,
475
],
[
475,
24,
412
]
],
[
[
776,
24,
407
],
[
407,
63,
412
]
],
[
[
776,
63,
1594
],
[
1594,
24,
1105
],
[
1105,
24,
412
]
],
[
[
776,
63,
543
],
[
543,
63,
1594
],
[
1594,
24,
412
]
],
[
[
776,
24,
830
],
[
830,
63,
1594
],
[
1594,
24,
412
]
],
[
[
776,
64,
475
],
[
475,
24,
1594
],
[
1594,
24,
412
]
],
[
[
776,
64,
593
],
[
593,
64,
475
],
[
475,
24,
412
]
]
]
| [
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Molindone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
]
]
| Molindone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Molindone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Molindone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Molindone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline |
DB00193 | DB00358 | 534 | 1,010 | [
"DDInter1841",
"DDInter1140"
]
| Tramadol | Mefloquine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [dul | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953] | Major | 2 | [
[
[
534,
25,
1010
]
],
[
[
534,
6,
8374
],
[
8374,
45,
1010
]
],
[
[
534,
21,
28789
],
[
28789,
60,
1010
]
],
[
[
534,
25,
1311
],
[
1311,
62,
1010
]
],
[
[
534,
23,
112
],
[
112,
62,
1010
]
],
[
[
534,
24,
823
],
[
823,
63,
1010
]
],
[
[
534,
63,
521
],
[
521,
24,
1010
]
],
[
[
534,
25,
401
],
[
401,
63,
1010
]
],
[
[
534,
24,
1181
],
[
1181,
24,
1010
]
],
[
[
534,
25,
608
],
[
608,
24,
1010
]
]
]
| [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
]
]
| Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Tramadol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Mefloquine (Compound)
Tramadol may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Tramadol may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Tramadol may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine |
DB00163 | DB01005 | 1,461 | 995 | [
"DDInter1943",
"DDInter894"
]
| Vitamin E | Hydroxyurea | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects. | Moderate | 1 | [
[
[
1461,
24,
995
]
],
[
[
1461,
24,
869
],
[
869,
63,
995
]
],
[
[
1461,
24,
147
],
[
147,
24,
995
]
],
[
[
1461,
62,
66
],
[
66,
24,
995
]
],
[
[
1461,
23,
1531
],
[
1531,
63,
995
]
],
[
[
1461,
23,
1377
],
[
1377,
64,
995
]
],
[
[
1461,
62,
1057
],
[
1057,
25,
995
]
],
[
[
1461,
24,
1064
],
[
1064,
25,
995
]
],
[
[
1461,
24,
869
],
[
869,
21,
29429
],
[
29429,
60,
995
]
],
[
[
1461,
24,
147
],
[
147,
5,
11555
],
[
11555,
44,
995
]
]
]
| [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroxyurea"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Hydroxyurea"
]
]
]
| Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Hydroxyurea
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Hydroxyurea
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Hydroxyurea
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Hydroxyurea (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Hydroxyurea (Compound) |
DB00108 | DB00307 | 1,066 | 1,101 | [
"DDInter1268",
"DDInter202"
]
| Natalizumab | Bexarotene | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023. | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Major | 2 | [
[
[
1066,
25,
1101
]
],
[
[
1066,
25,
1419
],
[
1419,
62,
1101
]
],
[
[
1066,
25,
168
],
[
168,
23,
1101
]
],
[
[
1066,
64,
66
],
[
66,
24,
1101
]
],
[
[
1066,
25,
287
],
[
287,
63,
1101
]
],
[
[
1066,
24,
496
],
[
496,
63,
1101
]
],
[
[
1066,
25,
1224
],
[
1224,
64,
1101
]
],
[
[
1066,
64,
268
],
[
268,
25,
1101
]
],
[
[
1066,
24,
1412
],
[
1412,
64,
1101
]
],
[
[
1066,
25,
1064
],
[
1064,
25,
1101
]
]
]
| [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cytarabine"
],
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
],
[
"Calaspargase pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]
]
]
| Natalizumab may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Natalizumab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Natalizumab may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Natalizumab may lead to a major life threatening interaction when taken with Cytarabine and Cytarabine may lead to a major life threatening interaction when taken with Bexarotene
Natalizumab may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bexarotene
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may lead to a major life threatening interaction when taken with Bexarotene
Natalizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Bexarotene |
DB01234 | DB15328 | 1,220 | 829 | [
"DDInter513",
"DDInter1896"
]
| Dexamethasone | Ubrogepant | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clinical development.[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative to its predecessors. Several parenteral monoclonal antibodies acting against the CGRP pathway (e.g. [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years. Ubrogepant was approved by Health Canada on November 10, 2022. Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages. They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular disease. The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment of this debilitating condition. | Moderate | 1 | [
[
[
1220,
24,
829
]
],
[
[
1220,
25,
1476
],
[
1476,
24,
829
]
],
[
[
1220,
24,
1468
],
[
1468,
24,
829
]
],
[
[
1220,
63,
883
],
[
883,
24,
829
]
],
[
[
1220,
63,
609
],
[
609,
25,
829
]
],
[
[
1220,
24,
760
],
[
760,
25,
829
]
],
[
[
1220,
25,
1476
],
[
1476,
63,
1468
],
[
1468,
24,
829
]
],
[
[
1220,
24,
1468
],
[
1468,
24,
1476
],
[
1476,
24,
829
]
],
[
[
1220,
25,
124
],
[
124,
24,
1476
],
[
1476,
24,
829
]
],
[
[
1220,
63,
883
],
[
883,
24,
1476
],
[
1476,
24,
829
]
]
]
| [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
]
]
| Dexamethasone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ubrogepant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Ubrogepant
Dexamethasone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Dexamethasone may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant |
DB04845 | DB06168 | 309 | 1,531 | [
"DDInter1001",
"DDInter281"
]
| Ixabepilone | Canakinumab | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients. | Moderate | 1 | [
[
[
309,
24,
1531
]
],
[
[
309,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
309,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
309,
63,
1213
],
[
1213,
24,
1531
]
],
[
[
309,
24,
1683
],
[
1683,
24,
1531
]
],
[
[
309,
62,
60
],
[
60,
24,
1531
]
],
[
[
309,
64,
1066
],
[
1066,
25,
1531
]
],
[
[
309,
24,
980
],
[
980,
64,
1531
]
],
[
[
309,
25,
375
],
[
375,
64,
1531
]
],
[
[
309,
63,
1461
],
[
1461,
24,
377
],
[
377,
24,
1531
]
]
]
| [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
]
]
| Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Ixabepilone may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Canakinumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may lead to a major life threatening interaction when taken with Canakinumab
Ixabepilone may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Canakinumab
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab |
DB01030 | DB08901 | 869 | 1,468 | [
"DDInter1835",
"DDInter1492"
]
| Topotecan | Ponatinib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
869,
24,
1468
]
],
[
[
869,
24,
478
],
[
478,
24,
1468
]
],
[
[
869,
6,
17404
],
[
17404,
45,
1468
]
],
[
[
869,
18,
2030
],
[
2030,
45,
1468
]
],
[
[
869,
7,
7478
],
[
7478,
46,
1468
]
],
[
[
869,
18,
5235
],
[
5235,
46,
1468
]
],
[
[
869,
18,
3741
],
[
3741,
57,
1468
]
],
[
[
869,
7,
20113
],
[
20113,
57,
1468
]
],
[
[
869,
21,
28852
],
[
28852,
60,
1468
]
],
[
[
869,
64,
589
],
[
589,
24,
1468
]
]
]
| [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"ABL1"
],
[
"ABL1",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"TRAPPC6A"
],
[
"TRAPPC6A",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"AARS"
],
[
"AARS",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"OXA1L"
],
[
"OXA1L",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
]
]
| Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Topotecan (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Ponatinib (Compound)
Topotecan (Compound) downregulates ABL1 (Gene) and ABL1 (Gene) is bound by Ponatinib (Compound)
Topotecan (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Ponatinib (Compound)
Topotecan (Compound) downregulates AARS (Gene) and AARS (Gene) is upregulated by Ponatinib (Compound)
Topotecan (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Ponatinib (Compound)
Topotecan (Compound) upregulates IER3 (Gene) and IER3 (Gene) is downregulated by Ponatinib (Compound)
Topotecan (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Ponatinib (Compound)
Topotecan may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib |
DB00348 | DB08873 | 254 | 74 | [
"DDInter1300",
"DDInter221"
]
| Nitisinone | Boceprevir | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs . Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with , , and . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination with , , and as first line therapy for Hepatitis C . Boceprevir, , , and are used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality . Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination with , , and [FDA Label]. Victrelis is no longer widely used as interferon-free therapies have been developed. | Moderate | 1 | [
[
[
254,
24,
74
]
],
[
[
254,
21,
28821
],
[
28821,
60,
74
]
],
[
[
254,
24,
1374
],
[
1374,
23,
74
]
],
[
[
254,
24,
1220
],
[
1220,
24,
74
]
],
[
[
254,
24,
1634
],
[
1634,
63,
74
]
],
[
[
254,
63,
1101
],
[
1101,
24,
74
]
],
[
[
254,
24,
129
],
[
129,
64,
74
]
],
[
[
254,
24,
392
],
[
392,
25,
74
]
],
[
[
254,
21,
28821
],
[
28821,
60,
310
],
[
310,
24,
74
]
],
[
[
254,
21,
28646
],
[
28646,
60,
1075
],
[
1075,
40,
74
]
]
]
| [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Sepsis"
],
[
"Sepsis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
],
[
"Avatrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Sepsis"
],
[
"Sepsis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telaprevir"
],
[
"Telaprevir",
"{u} (Compound) resembles {v} (Compound)",
"Boceprevir"
]
]
]
| Nitisinone (Compound) causes Sepsis (Side Effect) and Sepsis (Side Effect) is caused by Boceprevir (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Boceprevir
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag and Avatrombopag may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Boceprevir
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Boceprevir
Nitisinone (Compound) causes Sepsis (Side Effect) and Sepsis (Side Effect) is caused by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir
Nitisinone (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Telaprevir (Compound) and Telaprevir (Compound) resembles Boceprevir (Compound) |
DB01250 | DB15066 | 712 | 445 | [
"DDInter1334",
"DDInter821"
]
| Olsalazine | Givosiran | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene. Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151] | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders. | Moderate | 1 | [
[
[
712,
24,
445
]
],
[
[
712,
63,
1555
],
[
1555,
24,
445
]
],
[
[
712,
24,
123
],
[
123,
24,
445
]
],
[
[
712,
1,
50
],
[
50,
24,
445
]
],
[
[
712,
62,
126
],
[
126,
24,
445
]
],
[
[
712,
25,
1211
],
[
1211,
25,
445
]
],
[
[
712,
64,
258
],
[
258,
25,
445
]
],
[
[
712,
63,
1555
],
[
1555,
24,
850
],
[
850,
24,
445
]
],
[
[
712,
63,
1272
],
[
1272,
63,
1555
],
[
1555,
24,
445
]
],
[
[
712,
24,
123
],
[
123,
63,
1039
],
[
1039,
24,
445
]
]
]
| [
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfasalazine"
],
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
],
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
],
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
]
]
| Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Olsalazine (Compound) resembles Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Olsalazine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Olsalazine may lead to a major life threatening interaction when taken with Ioxilan and Ioxilan may lead to a major life threatening interaction when taken with Givosiran
Olsalazine may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol may lead to a major life threatening interaction when taken with Givosiran
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran |
DB00365 | DB06176 | 839 | 1,342 | [
"DDInter842",
"DDInter1616"
]
| Grepafloxacin | Romidepsin | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
839,
25,
1342
]
],
[
[
839,
23,
112
],
[
112,
23,
1342
]
],
[
[
839,
25,
485
],
[
485,
24,
1342
]
],
[
[
839,
25,
1616
],
[
1616,
63,
1342
]
],
[
[
839,
24,
1478
],
[
1478,
63,
1342
]
],
[
[
839,
64,
1010
],
[
1010,
24,
1342
]
],
[
[
839,
24,
355
],
[
355,
24,
1342
]
],
[
[
839,
23,
869
],
[
869,
24,
1342
]
],
[
[
839,
25,
985
],
[
985,
64,
1342
]
],
[
[
839,
64,
702
],
[
702,
25,
1342
]
]
]
| [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
]
]
| Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Grepafloxacin may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Grepafloxacin may lead to a major life threatening interaction when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Grepafloxacin may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Grepafloxacin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Romidepsin
Grepafloxacin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Romidepsin |
DB00011 | DB12240 | 1,451 | 110 | [
"DDInter944",
"DDInter1485"
]
| Interferon alfa-n1 | Polatuzumab vedotin | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab. Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 and was approved by Health Canada on July 9, 2020. | Moderate | 1 | [
[
[
1451,
24,
110
]
],
[
[
1451,
24,
467
],
[
467,
24,
110
]
],
[
[
1451,
63,
491
],
[
491,
24,
110
]
],
[
[
1451,
24,
148
],
[
148,
63,
110
]
],
[
[
1451,
25,
507
],
[
507,
25,
110
]
],
[
[
1451,
24,
908
],
[
908,
25,
110
]
],
[
[
1451,
25,
676
],
[
676,
64,
110
]
],
[
[
1451,
63,
1057
],
[
1057,
25,
110
]
],
[
[
1451,
24,
467
],
[
467,
24,
129
],
[
129,
23,
110
]
],
[
[
1451,
24,
268
],
[
268,
24,
467
],
[
467,
24,
110
]
]
]
| [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
]
]
| Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Polatuzumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin |
DB00963 | DB06723 | 1,263 | 115 | [
"DDInter241",
"DDInter58"
]
| Bromfenac | Aluminum hydroxide | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
1263,
23,
115
]
],
[
[
1263,
63,
870
],
[
870,
23,
115
]
],
[
[
1263,
24,
1220
],
[
1220,
23,
115
]
],
[
[
1263,
62,
752
],
[
752,
23,
115
]
],
[
[
1263,
25,
1468
],
[
1468,
62,
115
]
],
[
[
1263,
1,
831
],
[
831,
23,
115
]
],
[
[
1263,
25,
1213
],
[
1213,
24,
115
]
],
[
[
1263,
24,
1411
],
[
1411,
24,
115
]
],
[
[
1263,
63,
1479
],
[
1479,
24,
115
]
],
[
[
1263,
25,
405
],
[
405,
63,
115
]
]
]
| [
[
[
"Bromfenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} (Compound) resembles {v} (Compound)",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
]
]
| Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Bromfenac may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Bromfenac may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Bromfenac (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Bromfenac may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Bromfenac may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide |
DB00938 | DB14723 | 455 | 159 | [
"DDInter1635",
"DDInter1026"
]
| Salmeterol | Larotrectinib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
455,
24,
159
]
],
[
[
455,
24,
222
],
[
222,
23,
159
]
],
[
[
455,
63,
1230
],
[
1230,
23,
159
]
],
[
[
455,
24,
1375
],
[
1375,
24,
159
]
],
[
[
455,
63,
78
],
[
78,
24,
159
]
],
[
[
455,
23,
1486
],
[
1486,
24,
159
]
],
[
[
455,
24,
1654
],
[
1654,
63,
159
]
],
[
[
455,
62,
251
],
[
251,
24,
159
]
],
[
[
455,
25,
772
],
[
772,
24,
159
]
],
[
[
455,
24,
1568
],
[
1568,
25,
159
]
]
]
| [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
]
]
| Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Salmeterol may lead to a major life threatening interaction when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Larotrectinib |
DB00983 | DB09078 | 480 | 1,228 | [
"DDInter776",
"DDInter1036"
]
| Formoterol | Lenvatinib | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Moderate | 1 | [
[
[
480,
24,
1228
]
],
[
[
480,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
480,
24,
938
],
[
938,
63,
1228
]
],
[
[
480,
24,
609
],
[
609,
24,
1228
]
],
[
[
480,
74,
1052
],
[
1052,
24,
1228
]
],
[
[
480,
24,
1069
],
[
1069,
25,
1228
]
],
[
[
480,
63,
1425
],
[
1425,
25,
1228
]
],
[
[
480,
64,
17
],
[
17,
25,
1228
]
],
[
[
480,
24,
982
],
[
982,
64,
1228
]
],
[
[
480,
25,
351
],
[
351,
64,
1228
]
]
]
| [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Formoterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
]
]
| Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Formoterol (Compound) resembles Ritodrine (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Lenvatinib
Formoterol may lead to a major life threatening interaction when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Lenvatinib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lenvatinib
Formoterol may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Lenvatinib |
DB00637 | DB00927 | 1,557 | 1,559 | [
"DDInter128",
"DDInter712"
]
| Astemizole | Famotidine | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Moderate | 1 | [
[
[
1557,
24,
1559
]
],
[
[
1557,
18,
10375
],
[
10375,
57,
1559
]
],
[
[
1557,
23,
1247
],
[
1247,
62,
1559
]
],
[
[
1557,
24,
286
],
[
286,
62,
1559
]
],
[
[
1557,
23,
112
],
[
112,
23,
1559
]
],
[
[
1557,
64,
798
],
[
798,
23,
1559
]
],
[
[
1557,
24,
594
],
[
594,
63,
1559
]
],
[
[
1557,
64,
758
],
[
758,
24,
1559
]
],
[
[
1557,
24,
1664
],
[
1664,
24,
1559
]
],
[
[
1557,
25,
478
],
[
478,
63,
1559
]
]
]
| [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
]
]
| Astemizole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Famotidine (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Famotidine
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Famotidine
Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Famotidine
Astemizole may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Famotidine
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Astemizole may lead to a major life threatening interaction when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Astemizole may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine |
DB00377 | DB06663 | 1,494 | 1,154 | [
"DDInter1382",
"DDInter1398"
]
| Palonosetron | Pasireotide | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1494,
25,
1154
]
],
[
[
1494,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1494,
23,
112
],
[
112,
23,
1154
]
],
[
[
1494,
24,
62
],
[
62,
24,
1154
]
],
[
[
1494,
24,
1662
],
[
1662,
63,
1154
]
],
[
[
1494,
63,
867
],
[
867,
24,
1154
]
],
[
[
1494,
64,
1302
],
[
1302,
25,
1154
]
],
[
[
1494,
24,
679
],
[
679,
25,
1154
]
],
[
[
1494,
25,
1011
],
[
1011,
64,
1154
]
],
[
[
1494,
24,
124
],
[
124,
64,
1154
]
]
]
| [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
],
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Protriptyline"
],
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
],
[
"Sevoflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
]
]
| Palonosetron (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Palonosetron may lead to a major life threatening interaction when taken with Protriptyline and Protriptyline may lead to a major life threatening interaction when taken with Pasireotide
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Sevoflurane and Sevoflurane may lead to a major life threatening interaction when taken with Pasireotide
Palonosetron may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Pasireotide
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Pasireotide |
DB01238 | DB06616 | 673 | 594 | [
"DDInter118",
"DDInter224"
]
| Aripiprazole | Bosutinib | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Moderate | 1 | [
[
[
673,
24,
594
]
],
[
[
673,
63,
883
],
[
883,
1,
594
]
],
[
[
673,
6,
8374
],
[
8374,
45,
594
]
],
[
[
673,
7,
1986
],
[
1986,
46,
594
]
],
[
[
673,
21,
29231
],
[
29231,
60,
594
]
],
[
[
673,
62,
112
],
[
112,
23,
594
]
],
[
[
673,
63,
1559
],
[
1559,
24,
594
]
],
[
[
673,
24,
1040
],
[
1040,
63,
594
]
],
[
[
673,
24,
1374
],
[
1374,
24,
594
]
],
[
[
673,
74,
477
],
[
477,
24,
594
]
]
]
| [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) upregulates {v} (Gene)",
"INSIG1"
],
[
"INSIG1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
]
]
| Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Aripiprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Aripiprazole (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Bosutinib (Compound)
Aripiprazole (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Aripiprazole (Compound) resembles Cilostazol (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib |
DB00574 | DB01183 | 121 | 173 | [
"DDInter717",
"DDInter1262"
]
| Fenfluramine | Naloxone | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors. When taken in large quantities, opioid medications such as [morphine], [hydromorphone], [methadone], [heroin], or [fentanyl] are capable of causing life-threatening symptoms such as respiratory depression, reduced heart rate, slurred speech, drowsiness, and constricted pupils.[A234594,L33724] If untreated, this can progress to vomiting, absent pulse and breathing, loss of consciousness, and even death. Naloxone is indicated for the rapid reversal of these symptoms of central nervous system depression in opioid overdose. It's important to note that naloxone only works on opioid receptors within the body, and is therefore not capable of reversing the effects of non-opioid medications such as stimulants like [methamphetamine] or [cocaine], or benzodiazepines like [lorazepam] or [diazepam]. Also known as the brand name product Narcan, naloxone is currently available by intramuscular (IM) or subcutaneous (SubQ) injection, nasal spray, or intravenous (IV) infusion.[L33729,L33739] Naloxone IM injections are commonly available in the form of "kits", which is ideal for making overdose treatment accessible and readily available for administration by minimally trained individuals within the community. Kits commonly include the supplies necessary to treat an overdose in a non-medical setting such as alcohol swabs, syringes, a rescue breathing mask, and instructions for use. Frequently also carried by medical and emergency personnel and at events known to be associated with heavy drug use like music festivals, naloxone kits are considered a key component of harm reduction strategies. There are over-the-counter nasal sprays available. When injected intramuscularly (IM), naloxone acts within three to five minutes. Administration of naloxone is associated with very few side effects. Notably, if injected into a person not currently using opioid medications, there would be no noticeable effects at all. However, for individuals using opioid medications or experiencing an overdose, IM injection of naloxone rapidly reverses opioid effects and can cause the injected individual to immediately experience withdrawal symptoms. Common symptoms of opioid withdrawal include nausea, vomiting, sweating, runny nose, aches, and diarrhea. Although certainly physically uncomfortable, opioid withdrawal symptoms are not life-threatening; administration of naloxone is, therefore, appropriate for any person appearing to have any symptoms of an opioid overdose. Due to its short duration of action, persons injected with naloxone should be monitored for responsiveness and potentially injected a second time or taken to the hospital. Naloxone is also available within the combination product Suboxone with the opioid medication [buprenorphine].[L33714,L33719] Suboxone is used for the maintenance treatment of opioid dependence and addiction.[L33714,L33719] When taken orally, naloxone has no pharmacological effect and does not reduce the effectiveness of the opioid effect of buprenorphine.[L33714,L33719] The primary purpose of including naloxone within Suboxone is to act as a deterrent to injection, as injected naloxone would rapidly reverse the effects of buprenorphine.[L33714,L33719] Naloxone was granted FDA approval on 13 April 1971. | Minor | 0 | [
[
[
121,
23,
173
]
],
[
[
121,
24,
314
],
[
314,
24,
173
]
],
[
[
121,
63,
475
],
[
475,
24,
173
]
],
[
[
121,
64,
534
],
[
534,
24,
173
]
],
[
[
121,
25,
1322
],
[
1322,
24,
173
]
],
[
[
121,
25,
768
],
[
768,
63,
173
]
],
[
[
121,
24,
1359
],
[
1359,
63,
173
]
],
[
[
121,
24,
560
],
[
560,
74,
173
]
],
[
[
121,
63,
421
],
[
421,
35,
173
]
],
[
[
121,
24,
314
],
[
314,
1,
509
],
[
509,
40,
173
]
]
]
| [
[
[
"Fenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alfentanil"
],
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
],
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
],
[
"Dezocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
],
[
"Oxymorphone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxone"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} (Compound) resembles {v} (Compound)",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} (Compound) resembles {v} (Compound)",
"Naloxone"
]
]
]
| Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fenfluramine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fenfluramine may lead to a major life threatening interaction when taken with Alfentanil and Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fenfluramine may lead to a major life threatening interaction when taken with Tapentadol and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone and Oxymorphone (Compound) resembles Naloxone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Naloxone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine (Compound) resembles Buprenorphine (Compound) and Buprenorphine (Compound) resembles Naloxone (Compound) |
DB06605 | DB11569 | 1,409 | 1,093 | [
"DDInter108",
"DDInter1003"
]
| Apixaban | Ixekizumab | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. | Moderate | 1 | [
[
[
1409,
24,
1093
]
],
[
[
1409,
63,
1461
],
[
1461,
23,
1093
]
],
[
[
1409,
63,
1683
],
[
1683,
24,
1093
]
],
[
[
1409,
64,
1236
],
[
1236,
24,
1093
]
],
[
[
1409,
24,
1586
],
[
1586,
24,
1093
]
],
[
[
1409,
24,
1456
],
[
1456,
63,
1093
]
],
[
[
1409,
63,
1057
],
[
1057,
25,
1093
]
],
[
[
1409,
24,
375
],
[
375,
25,
1093
]
],
[
[
1409,
63,
1461
],
[
1461,
62,
66
],
[
66,
24,
1093
]
],
[
[
1409,
63,
1683
],
[
1683,
23,
1114
],
[
1114,
23,
1093
]
]
]
| [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
],
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ixekizumab"
]
]
]
| Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Apixaban may lead to a major life threatening interaction when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine and Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ixekizumab
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Ixekizumab
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab |
DB00224 | DB08816 | 215 | 578 | [
"DDInter917",
"DDInter1802"
]
| Indinavir | Ticagrelor | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Major | 2 | [
[
[
215,
25,
578
]
],
[
[
215,
6,
4973
],
[
4973,
45,
578
]
],
[
[
215,
21,
28646
],
[
28646,
60,
578
]
],
[
[
215,
25,
1135
],
[
1135,
62,
578
]
],
[
[
215,
24,
723
],
[
723,
24,
578
]
],
[
[
215,
24,
868
],
[
868,
63,
578
]
],
[
[
215,
25,
1297
],
[
1297,
63,
578
]
],
[
[
215,
25,
617
],
[
617,
24,
578
]
],
[
[
215,
63,
1324
],
[
1324,
24,
578
]
],
[
[
215,
23,
222
],
[
222,
24,
578
]
]
]
| [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Indinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
]
]
| Indinavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Indinavir (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Indinavir may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Indinavir may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Indinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor |
DB00983 | DB06788 | 480 | 1,616 | [
"DDInter776",
"DDInter864"
]
| Formoterol | Histrelin | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007). | Moderate | 1 | [
[
[
480,
24,
1616
]
],
[
[
480,
63,
1664
],
[
1664,
24,
1616
]
],
[
[
480,
24,
623
],
[
623,
24,
1616
]
],
[
[
480,
24,
927
],
[
927,
63,
1616
]
],
[
[
480,
74,
1052
],
[
1052,
24,
1616
]
],
[
[
480,
24,
57
],
[
57,
25,
1616
]
],
[
[
480,
24,
1375
],
[
1375,
64,
1616
]
],
[
[
480,
63,
684
],
[
684,
25,
1616
]
],
[
[
480,
64,
17
],
[
17,
25,
1616
]
],
[
[
480,
25,
877
],
[
877,
64,
1616
]
]
]
| [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Formoterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
]
]
| Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Formoterol (Compound) resembles Ritodrine (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Histrelin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine may lead to a major life threatening interaction when taken with Histrelin
Formoterol may lead to a major life threatening interaction when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Histrelin
Formoterol may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Histrelin |
DB01238 | DB01259 | 673 | 392 | [
"DDInter118",
"DDInter1024"
]
| Aripiprazole | Lapatinib | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Moderate | 1 | [
[
[
673,
24,
392
]
],
[
[
673,
6,
4973
],
[
4973,
45,
392
]
],
[
[
673,
21,
29429
],
[
29429,
60,
392
]
],
[
[
673,
62,
112
],
[
112,
23,
392
]
],
[
[
673,
63,
918
],
[
918,
24,
392
]
],
[
[
673,
24,
1151
],
[
1151,
63,
392
]
],
[
[
673,
24,
820
],
[
820,
24,
392
]
],
[
[
673,
74,
477
],
[
477,
24,
392
]
],
[
[
673,
1,
827
],
[
827,
24,
392
]
],
[
[
673,
40,
1630
],
[
1630,
24,
392
]
]
]
| [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) resembles {v} (Compound)",
"Trazodone"
],
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Aripiprazole",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
]
]
| Aripiprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Aripiprazole (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Aripiprazole (Compound) resembles Cilostazol (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Aripiprazole (Compound) resembles Trazodone (Compound) and Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Aripiprazole (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib |
DB01240 | DB15035 | 885 | 503 | [
"DDInter657",
"DDInter1959"
]
| Epoprostenol | Zanubrutinib | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia. | Major | 2 | [
[
[
885,
25,
503
]
],
[
[
885,
63,
222
],
[
222,
24,
503
]
],
[
[
885,
24,
765
],
[
765,
24,
503
]
],
[
[
885,
25,
39
],
[
39,
25,
503
]
],
[
[
885,
63,
1018
],
[
1018,
25,
503
]
],
[
[
885,
64,
500
],
[
500,
25,
503
]
],
[
[
885,
40,
1061
],
[
1061,
25,
503
]
],
[
[
885,
24,
578
],
[
578,
25,
503
]
],
[
[
885,
63,
1274
],
[
1274,
37,
503
]
],
[
[
885,
63,
222
],
[
222,
63,
1324
],
[
1324,
24,
503
]
]
]
| [
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} (Compound) resembles {v} (Compound)",
"Treprostinil"
],
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
]
]
| Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Epoprostenol may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Zanubrutinib
Epoprostenol may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Zanubrutinib
Epoprostenol (Compound) resembles Treprostinil (Compound) and Treprostinil may lead to a major life threatening interaction when taken with Zanubrutinib
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Zanubrutinib
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib and Flurbiprofen may lead to a major life threatening interaction when taken with Zanubrutinib
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib |
DB00564 | DB08826 | 1,236 | 1,292 | [
"DDInter293",
"DDInter489"
]
| Carbamazepine | Deferiprone | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. | Major | 2 | [
[
[
1236,
25,
1292
]
],
[
[
1236,
21,
28759
],
[
28759,
60,
1292
]
],
[
[
1236,
25,
1017
],
[
1017,
63,
1292
]
],
[
[
1236,
24,
1512
],
[
1512,
24,
1292
]
],
[
[
1236,
63,
482
],
[
482,
25,
1292
]
],
[
[
1236,
62,
1101
],
[
1101,
25,
1292
]
],
[
[
1236,
24,
1619
],
[
1619,
64,
1292
]
],
[
[
1236,
25,
1419
],
[
1419,
25,
1292
]
],
[
[
1236,
25,
214
],
[
214,
64,
1292
]
],
[
[
1236,
24,
4
],
[
4,
25,
1292
]
]
]
| [
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} (Compound) causes {v} (Side Effect)",
"Connective tissue disorder"
],
[
"Connective tissue disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
]
]
| Carbamazepine (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Deferiprone (Compound)
Carbamazepine may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Carbamazepine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Deferiprone
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Deferiprone
Carbamazepine may lead to a major life threatening interaction when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Deferiprone
Carbamazepine may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may lead to a major life threatening interaction when taken with Deferiprone
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Deferiprone |
DB00863 | DB08864 | 1,194 | 786 | [
"DDInter1568",
"DDInter1595"
]
| Ranitidine | Rilpivirine | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818] | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior. | Major | 2 | [
[
[
1194,
25,
786
]
],
[
[
1194,
23,
655
],
[
655,
1,
786
]
],
[
[
1194,
6,
8374
],
[
8374,
45,
786
]
],
[
[
1194,
21,
29343
],
[
29343,
60,
786
]
],
[
[
1194,
24,
594
],
[
594,
24,
786
]
],
[
[
1194,
64,
543
],
[
543,
24,
786
]
],
[
[
1194,
25,
1213
],
[
1213,
24,
786
]
],
[
[
1194,
23,
1283
],
[
1283,
24,
786
]
],
[
[
1194,
24,
1476
],
[
1476,
63,
786
]
],
[
[
1194,
23,
286
],
[
286,
63,
786
]
]
]
| [
[
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} (Compound) resembles {v} (Compound)",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} (Compound) causes {v} (Side Effect)",
"Blood creatinine increased"
],
[
"Blood creatinine increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
]
]
| Ranitidine may cause a minor interaction that can limit clinical effects when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Ranitidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Ranitidine (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Rilpivirine (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Ranitidine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Ranitidine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine |
DB00209 | DB00382 | 352 | 62 | [
"DDInter1886",
"DDInter1734"
]
| Trospium | Tacrine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007. | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Moderate | 1 | [
[
[
352,
24,
62
]
],
[
[
352,
24,
1507
],
[
1507,
63,
62
]
],
[
[
352,
24,
1594
],
[
1594,
24,
62
]
],
[
[
352,
35,
1192
],
[
1192,
63,
62
]
],
[
[
352,
24,
1507
],
[
1507,
63,
19
],
[
19,
63,
62
]
],
[
[
352,
24,
19
],
[
19,
24,
1507
],
[
1507,
63,
62
]
],
[
[
352,
35,
1192
],
[
1192,
63,
1507
],
[
1507,
63,
62
]
],
[
[
352,
35,
262
],
[
262,
24,
1507
],
[
1507,
63,
62
]
],
[
[
352,
24,
752
],
[
752,
23,
848
],
[
848,
62,
62
]
],
[
[
352,
21,
28722
],
[
28722,
60,
1001
],
[
1001,
62,
62
]
]
]
| [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tacrine"
]
],
[
[
"Trospium",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tacrine"
]
]
]
| Trospium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Trospium (Compound) resembles Glycopyrronium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Trospium (Compound) resembles Glycopyrronium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Trospium (Compound) resembles Clidinium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Tacrine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ibuprofen and Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Tacrine
Trospium (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Mechlorethamine (Compound) and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Tacrine |
DB01138 | DB13074 | 804 | 877 | [
"DDInter1726",
"DDInter1110"
]
| Sulfinpyrazone | Macimorelin | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Moderate | 1 | [
[
[
804,
24,
877
]
],
[
[
804,
24,
1320
],
[
1320,
24,
877
]
],
[
[
804,
63,
1479
],
[
1479,
24,
877
]
],
[
[
804,
62,
1101
],
[
1101,
24,
877
]
],
[
[
804,
24,
478
],
[
478,
25,
877
]
],
[
[
804,
63,
1424
],
[
1424,
25,
877
]
],
[
[
804,
25,
1213
],
[
1213,
25,
877
]
],
[
[
804,
24,
1320
],
[
1320,
63,
651
],
[
651,
24,
877
]
],
[
[
804,
63,
1479
],
[
1479,
23,
651
],
[
651,
24,
877
]
],
[
[
804,
62,
1101
],
[
1101,
24,
1320
],
[
1320,
24,
877
]
]
]
| [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
]
]
| Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Macimorelin
Sulfinpyrazone may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Macimorelin
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin |
DB01076 | DB12500 | 700 | 283 | [
"DDInter133",
"DDInter714"
]
| Atorvastatin | Fedratinib | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
700,
24,
283
]
],
[
[
700,
24,
466
],
[
466,
62,
283
]
],
[
[
700,
24,
351
],
[
351,
23,
283
]
],
[
[
700,
63,
1419
],
[
1419,
24,
283
]
],
[
[
700,
64,
600
],
[
600,
24,
283
]
],
[
[
700,
24,
951
],
[
951,
24,
283
]
],
[
[
700,
23,
578
],
[
578,
24,
283
]
],
[
[
700,
24,
159
],
[
159,
63,
283
]
],
[
[
700,
62,
303
],
[
303,
24,
283
]
],
[
[
700,
24,
1017
],
[
1017,
25,
283
]
]
]
| [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
]
| Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Atorvastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib |
DB01208 | DB11827 | 945 | 433 | [
"DDInter1705",
"DDInter669"
]
| Sparfloxacin | Ertugliflozin | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
945,
24,
433
]
],
[
[
945,
64,
959
],
[
959,
24,
433
]
],
[
[
945,
40,
1176
],
[
1176,
24,
433
]
],
[
[
945,
25,
609
],
[
609,
24,
433
]
],
[
[
945,
25,
1019
],
[
1019,
63,
433
]
],
[
[
945,
63,
688
],
[
688,
24,
433
]
],
[
[
945,
24,
659
],
[
659,
24,
433
]
],
[
[
945,
40,
246
],
[
246,
25,
433
]
],
[
[
945,
64,
959
],
[
959,
62,
1103
],
[
1103,
23,
433
]
],
[
[
945,
64,
521
],
[
521,
25,
695
],
[
695,
24,
433
]
]
]
| [
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
]
]
| Sparfloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Sparfloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Sparfloxacin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Sparfloxacin may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Sparfloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Ertugliflozin
Sparfloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Sparfloxacin may lead to a major life threatening interaction when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin |
DB00308 | DB11837 | 347 | 1,297 | [
"DDInter901",
"DDInter1351"
]
| Ibutilide | Osilodrostat | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013. Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. Cushing's disease), and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication. | Major | 2 | [
[
[
347,
25,
1297
]
],
[
[
347,
23,
112
],
[
112,
23,
1297
]
],
[
[
347,
25,
401
],
[
401,
24,
1297
]
],
[
[
347,
24,
657
],
[
657,
24,
1297
]
],
[
[
347,
25,
971
],
[
971,
63,
1297
]
],
[
[
347,
64,
600
],
[
600,
24,
1297
]
],
[
[
347,
63,
608
],
[
608,
24,
1297
]
],
[
[
347,
25,
351
],
[
351,
25,
1297
]
],
[
[
347,
25,
982
],
[
982,
64,
1297
]
],
[
[
347,
40,
17
],
[
17,
25,
1297
]
]
]
| [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ibutilide",
"{u} (Compound) resembles {v} (Compound)",
"Sotalol"
],
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
]
]
| Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Ibutilide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Ibutilide may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Ibutilide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Ibutilide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Osilodrostat
Ibutilide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Osilodrostat
Ibutilide (Compound) resembles Sotalol (Compound) and Sotalol may lead to a major life threatening interaction when taken with Osilodrostat |
DB00539 | DB09065 | 11 | 760 | [
"DDInter1837",
"DDInter424"
]
| Toremifene | Cobicistat | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Major | 2 | [
[
[
11,
25,
760
]
],
[
[
11,
24,
479
],
[
479,
23,
760
]
],
[
[
11,
64,
1230
],
[
1230,
23,
760
]
],
[
[
11,
63,
1101
],
[
1101,
23,
760
]
],
[
[
11,
25,
1374
],
[
1374,
23,
760
]
],
[
[
11,
25,
938
],
[
938,
63,
760
]
],
[
[
11,
24,
875
],
[
875,
24,
760
]
],
[
[
11,
25,
1664
],
[
1664,
24,
760
]
],
[
[
11,
64,
534
],
[
534,
24,
760
]
],
[
[
11,
35,
1423
],
[
1423,
24,
760
]
]
]
| [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
],
[
"Ospemifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
]
]
| Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Toremifene may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Toremifene may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Toremifene may lead to a major life threatening interaction when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Toremifene may lead to a major life threatening interaction when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Toremifene may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Toremifene (Compound) resembles Ospemifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene and Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat |
DB00813 | DB11767 | 704 | 1,583 | [
"DDInter722",
"DDInter1643"
]
| Fentanyl | Sarilumab | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily. Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms. | Moderate | 1 | [
[
[
704,
24,
1583
]
],
[
[
704,
64,
267
],
[
267,
24,
1583
]
],
[
[
704,
24,
1362
],
[
1362,
24,
1583
]
],
[
[
704,
40,
576
],
[
576,
24,
1583
]
],
[
[
704,
1,
371
],
[
371,
24,
1583
]
],
[
[
704,
25,
384
],
[
384,
24,
1583
]
],
[
[
704,
63,
58
],
[
58,
24,
1583
]
],
[
[
704,
24,
1683
],
[
1683,
25,
1583
]
],
[
[
704,
63,
1184
],
[
1184,
25,
1583
]
],
[
[
704,
24,
1259
],
[
1259,
64,
1583
]
]
]
| [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Propafenone"
],
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
]
]
| Fentanyl may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Fentanyl (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Fentanyl (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Fentanyl may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Sarilumab
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Sarilumab |
DB01087 | DB11853 | 1,520 | 230 | [
"DDInter1520",
"DDInter1577"
]
| Primaquine | Relugolix | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer. In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. | Moderate | 1 | [
[
[
1520,
24,
230
]
],
[
[
1520,
24,
129
],
[
129,
23,
230
]
],
[
[
1520,
62,
112
],
[
112,
23,
230
]
],
[
[
1520,
63,
480
],
[
480,
24,
230
]
],
[
[
1520,
24,
1662
],
[
1662,
24,
230
]
],
[
[
1520,
24,
1619
],
[
1619,
63,
230
]
],
[
[
1520,
25,
1487
],
[
1487,
24,
230
]
],
[
[
1520,
25,
351
],
[
351,
25,
230
]
],
[
[
1520,
24,
392
],
[
392,
25,
230
]
],
[
[
1520,
64,
11
],
[
11,
25,
230
]
]
]
| [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
]
]
| Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Relugolix
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Primaquine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Relugolix
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Relugolix
Primaquine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Relugolix |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.